

Karel Pacak

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4091175/publications.pdf>

Version: 2024-02-01

497
papers

36,219
citations

2795

94
h-index

4750

169
g-index

509
all docs

509
docs citations

509
times ranked

19871
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | Personalized Management of Pheochromocytoma and Paraganglioma. <i>Endocrine Reviews</i> , 2022, 43, 199-239. | 8.9 | 127 |
| 2 | Sporadic Primary Pheochromocytoma: A Prospective Intraindividual Comparison of Six Imaging Tests (CT, MRI, and PET/CT Using ⁶⁸ Ga-DOTATATE, FDG, ¹⁸ F-FDOPA, and Tl-201) <i>Overlock 10 Tf 50 69</i> | 1.2 | 0 |
| 3 | Germline <i>SUCLG2</i> Variants in Patients With Pheochromocytoma and Paraganglioma. <i>Journal of the National Cancer Institute</i> , 2022, 114, 130-138. | 3.0 | 21 |
| 4 | Differences in clinical presentation and management between pre- and postsurgical diagnoses of urinary bladder paraganglioma: is there clinical relevance? A systematic review. <i>World Journal of Urology</i> , 2022, 40, 385-390. | 1.2 | 8 |
| 5 | New Insights on the Genetics of Pheochromocytoma and Paraganglioma and Its Clinical Implications. <i>Cancers</i> , 2022, 14, 594. | 1.7 | 33 |
| 6 | Personalized drug testing in human pheochromocytoma/paraganglioma primary cultures. <i>Endocrine-Related Cancer</i> , 2022, 29, 285-306. | 1.6 | 12 |
| 7 | Head/neck paragangliomas: focus on tumor location, mutational status and plasma methoxytyramine. <i>Endocrine-Related Cancer</i> , 2022, 29, 213-224. | 1.6 | 12 |
| 8 | Somatic Mosaicism of EPAS1 Mutations in Pacak-Zhuang Syndrome. <i>Endocrine Practice</i> , 2022, , . | 1.1 | 0 |
| 9 | Functional Imaging of Neuroendocrine Tumors: Stacking the Odds in a Patient's Favor. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, e3953-e3954. | 1.8 | 2 |
| 10 | Determinants of disease-specific survival in patients with and without metastatic pheochromocytoma and paraganglioma. <i>European Journal of Cancer</i> , 2022, 169, 32-41. | 1.3 | 18 |
| 11 | Supportive management of patients with pheochromocytoma/paraganglioma undergoing noninvasive treatment. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2022, 29, 294-301. | 1.2 | 3 |
| 12 | Phaeochromocytoma and pregnancy: looking towards better outcomes, less fear, and valuable recommendations. <i>Lancet Diabetes and Endocrinology</i> , 2021, 9, 2-3. | 5.5 | 6 |
| 13 | What Have We Learned from Molecular Biology of Paragangliomas and Pheochromocytomas?. <i>Endocrine Pathology</i> , 2021, 32, 134-153. | 5.2 | 22 |
| 14 | Pheochromocytoma Hypertensive Crisis. <i>Contemporary Endocrinology</i> , 2021, , 137-145. | 0.3 | 0 |
| 15 | Functional significance of germline EPAS1 variants. <i>Endocrine-Related Cancer</i> , 2021, 28, 97-109. | 1.6 | 6 |
| 16 | Developmental vascular malformations in EPAS1 gain-of-function syndrome. <i>JCI Insight</i> , 2021, 6, . | 2.3 | 14 |
| 17 | High-Specific-Activity-131I-MIBG versus 177Lu-DOTATATE Targeted Radionuclide Therapy for Metastatic Pheochromocytoma and Paraganglioma. <i>Clinical Cancer Research</i> , 2021, 27, 2989-2995. | 3.2 | 42 |
| 18 | Mannan-BAM, TLR Ligands, Anti-CD40 Antibody (MBTA) Vaccine Immunotherapy: A Review of Current Evidence and Applications in Glioblastoma. <i>International Journal of Molecular Sciences</i> , 2021, 22, 3455. | 1.8 | 7 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | Succinate Mediates Tumorigenic Effects via Succinate Receptor 1: Potential for New Targeted Treatment Strategies in Succinate Dehydrogenase Deficient Paragangliomas. <i>Frontiers in Endocrinology</i> , 2021, 12, 589451. | 1.5 | 25 |
| 20 | Somatostatin Receptors and Analogs in Pheochromocytoma and Paraganglioma: Old Players in a New Precision Medicine World. <i>Frontiers in Endocrinology</i> , 2021, 12, 625312. | 1.5 | 25 |
| 21 | Imaging of Small Intestine Neuroendocrine Neoplasms: Is SSTR PET the Holy Grail?. <i>Journal of Nuclear Medicine</i> , 2021, 62, 1347-1348. | 2.8 | 3 |
| 22 | Mannan-BAM, TLR ligands, and anti-CD40 immunotherapy in established murine pancreatic adenocarcinoma: understanding therapeutic potentials and limitations. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 3303-3312. | 2.0 | 5 |
| 23 | International consensus on initial screening and follow-up of asymptomatic SDHx mutation carriers. <i>Nature Reviews Endocrinology</i> , 2021, 17, 435-444. | 4.3 | 80 |
| 24 | Diagnostic Accuracy of Salivary Metanephrines in Pheochromocytomas and Paragangliomas. <i>Clinical Chemistry</i> , 2021, 67, 1090-1097. | 1.5 | 2 |
| 25 | Clinically Advanced Pheochromocytomas and Paragangliomas: A Comprehensive Genomic Profiling Study. <i>Cancers</i> , 2021, 13, 3312. | 1.7 | 9 |
| 26 | Imaging of Pheochromocytoma and Paraganglioma. <i>Journal of Nuclear Medicine</i> , 2021, 62, 1033-1042. | 2.8 | 50 |
| 27 | Reactive Oxygen Species: A Promising Therapeutic Target for SDHx-Mutated Pheochromocytoma and Paraganglioma. <i>Cancers</i> , 2021, 13, 3769. | 1.7 | 3 |
| 28 | A Clinical Challenge: Endocrine and Imaging Investigations of Adrenal Masses. <i>Journal of Nuclear Medicine</i> , 2021, 62, 26S-33S. | 2.8 | 8 |
| 29 | Identification of Immune Cell Infiltration in Murine Pheochromocytoma during Combined Mannan-BAM, TLR Ligand, and Anti-CD40 Antibody-Based Immunotherapy. <i>Cancers</i> , 2021, 13, 3942. | 1.7 | 7 |
| 30 | Identification of Isocitrate Dehydrogenase 2 (IDH2) Mutation in Carotid Body Paraganglioma. <i>Frontiers in Endocrinology</i> , 2021, 12, 731096. | 1.5 | 5 |
| 31 | Variants and Pitfalls of PET/CT in Neuroendocrine Tumors. <i>Seminars in Nuclear Medicine</i> , 2021, 51, 519-528. | 2.5 | 11 |
| 32 | A long noncoding RNA microRNA expression signature predicts metastatic signature in pheochromocytomas and paragangliomas. <i>Endocrine</i> , 2021, , 1. | 1.1 | 1 |
| 33 | Systemic Radiopharmaceutical Therapy of Pheochromocytoma and Paraganglioma. <i>Journal of Nuclear Medicine</i> , 2021, 62, 1192-1199. | 2.8 | 14 |
| 34 | A novel liquid biopsy (NETest) identifies paragangliomas and pheochromocytomas with high accuracy. <i>Endocrine-Related Cancer</i> , 2021, 28, 731-744. | 1.6 | 9 |
| 35 | Quantitative biomarkers allow the diagnosis of head and neck paraganglioma on multiparametric MRI. <i>European Journal of Radiology</i> , 2021, 143, 109911. | 1.2 | 3 |
| 36 | The Global Reading Room: Nuclear Medicine Imaging of Suspected Paraganglioma. <i>American Journal of Roentgenology</i> , 2021, 217, 1008-1009. | 1.0 | 1 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | Deep Membrane Proteome Profiling Reveals Overexpression of Prostate-Specific Membrane Antigen (PSMA) in High-Risk Human Paraganglioma and Pheochromocytoma, Suggesting New Theranostic Opportunity. <i>Molecules</i> , 2021, 26, 6567. | 1.7 | 4 |
| 38 | Surgical Resection of Pheochromocytomas and Paragangliomas is Associated with Lower Cholesterol Levels. <i>World Journal of Surgery</i> , 2020, 44, 552-560. | 0.8 | 4 |
| 39 | Long intergenic noncoding RNA profiles of pheochromocytoma and paraganglioma: A novel prognostic biomarker. <i>International Journal of Cancer</i> , 2020, 146, 2326-2335. | 2.3 | 14 |
| 40 | Prognostic and predictive value of nuclear imaging in endocrine oncology. <i>Endocrine</i> , 2020, 67, 9-19. | 1.1 | 9 |
| 41 | Vascular Changes in the Retina and Choroid of Patients With EPAS1 Gain-of-Function Mutation Syndrome. <i>JAMA Ophthalmology</i> , 2020, 138, 148. | 1.4 | 4 |
| 42 | Some Considerations in Treating Malignant Head and Neck Paragangliomas. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2020, 146, 209. | 1.2 | 2 |
| 43 | Pheochromocytoma and Paraganglioma Patients With Poor Survival Often Show Brown Adipose Tissue Activation. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 1176-1185. | 1.8 | 18 |
| 44 | Phosphoprotein-based biomarkers as predictors for cancer therapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 18401-18411. | 3.3 | 25 |
| 45 | Pathophysiology and Acute Management of Tachyarrhythmias in Pheochromocytoma. <i>Journal of the American College of Cardiology</i> , 2020, 76, 451-464. | 1.2 | 30 |
| 46 | Induction of Immune Response against Metastatic Tumors via Vaccination of Mannan- β AM, TLR Ligands, and Anti-CD40 Antibody (MBTA). <i>Advanced Therapeutics</i> , 2020, 3, 2000044. | 1.6 | 11 |
| 47 | Catecholamine physiology and its implications in patients with COVID-19. <i>Lancet Diabetes and Endocrinology</i> , 2020, 8, 978-986. | 5.5 | 49 |
| 48 | Emerging Treatments for Advanced/Metastatic Pheochromocytoma and Paraganglioma. <i>Current Treatment Options in Oncology</i> , 2020, 21, 85. | 1.3 | 43 |
| 49 | Phaeochromocytoma – advances through science, collaboration and spreading the word. <i>Nature Reviews Endocrinology</i> , 2020, 16, 621-622. | 4.3 | 8 |
| 50 | Neuraxial dysraphism in EPAS1-associated syndrome due to improper mesenchymal transition. <i>Neurology: Genetics</i> , 2020, 6, e414. | 0.9 | 5 |
| 51 | Metabolomics, machine learning and immunohistochemistry to predict succinate dehydrogenase mutational status in phaeochromocytomas and paragangliomas. <i>Journal of Pathology</i> , 2020, 251, 378-387. | 2.1 | 23 |
| 52 | Targeting pheochromocytoma/paraganglioma with polyamine inhibitors. <i>Metabolism: Clinical and Experimental</i> , 2020, 110, 154297. | 1.5 | 11 |
| 53 | Therapeutic Targeting of SDHB-Mutated Pheochromocytoma/Paraganglioma with Pharmacologic Ascorbic Acid. <i>Clinical Cancer Research</i> , 2020, 26, 3868-3880. | 3.2 | 29 |
| 54 | Molecular Imaging in the Era of Precision Medicine: Paraganglioma as a Template for Understanding Multiple Levels of Analysis. <i>Journal of Nuclear Medicine</i> , 2020, 61, 646-648. | 2.8 | 1 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 55 | Genetics, diagnosis, management and future directions of research of pheochromocytoma and paraganglioma: a position statement and consensus of the Working Group on Endocrine Hypertension of the European Society of Hypertension. <i>Journal of Hypertension</i> , 2020, 38, 1443-1456. | 0.3 | 190 |
| 56 | Clinical characteristics and outcomes of SDHB-related pheochromocytoma and paraganglioma in children and adolescents. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 1051-1063. | 1.2 | 30 |
| 57 | Clinical manifestations of Pacak-Zhuang syndrome in a male pediatric patient. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28096. | 0.8 | 4 |
| 58 | Role of 68Ga-DOTATATE PET/CT in a Case of SDHB-Related Pterygopalatine Fossa Paraganglioma Successfully Controlled with Octreotide. <i>Nuclear Medicine and Molecular Imaging</i> , 2020, 54, 48-52. | 0.6 | 9 |
| 59 | Targeting NRF2-Governed Glutathione Synthesis for SDHB-Mutated Pheochromocytoma and Paraganglioma. <i>Cancers</i> , 2020, 12, 280. | 1.7 | 23 |
| 60 | Genetic Determinants of Pheochromocytoma and Paraganglioma Imaging Phenotypes. <i>Journal of Nuclear Medicine</i> , 2020, 61, 643-645. | 2.8 | 7 |
| 61 | C-Terminal, but Not Intact, FGF23 and EPO Are Strongly Correlatively Elevated in Patients With Gain-of-Function Mutations in HIF2A: Clinical Evidence for EPO Regulating FGF23. <i>Journal of Bone and Mineral Research</i> , 2020, 36, 315-321. | 3.1 | 9 |
| 62 | Case Report: Primary Hypothyroidism Associated With Lutetium 177-DOTATATE Therapy for Metastatic Paraganglioma. <i>Frontiers in Endocrinology</i> , 2020, 11, 587065. | 1.5 | 4 |
| 63 | Comprehensive review of evaluation and management of cardiac paragangliomas. <i>Heart</i> , 2020, 106, 1202-1210. | 1.2 | 22 |
| 64 | A xenograft and cell line model of SDH-deficient pheochromocytoma derived from Sdhb+/Δ rats. <i>Endocrine-Related Cancer</i> , 2020, 27, 337-354. | 1.6 | 16 |
| 65 | Epidural anesthesia and hypotension in pheochromocytoma and paraganglioma. <i>Endocrine-Related Cancer</i> , 2020, 27, 519-527. | 1.6 | 7 |
| 66 | HIF2α supports pro-metastatic behavior in pheochromocytomas/paragangliomas. <i>Endocrine-Related Cancer</i> , 2020, 27, 625-640. | 1.6 | 33 |
| 67 | Pheochromocytoma/paraganglioma: recent updates in genetics, biochemistry, immunohistochemistry, metabolomics, imaging and therapeutic options. <i>Gland Surgery</i> , 2020, 9, 105-123. | 0.5 | 37 |
| 68 | 18F-FDOPA PET/CT accurately identifies MEN1-associated pheochromocytoma. <i>Endocrinology, Diabetes and Metabolism Case Reports</i> , 2020, 2020, . | 0.2 | 4 |
| 69 | A novel germline gain-of-function HIF2A mutation in hepatocellular carcinoma with polycythemia. <i>Aging</i> , 2020, 12, 5781-5791. | 1.4 | 4 |
| 70 | Metabolome-guided genomics to identify pathogenic variants in isocitrate dehydrogenase, fumarate hydratase, and succinate dehydrogenase genes in pheochromocytoma and paraganglioma. <i>Genetics in Medicine</i> , 2019, 21, 705-717. | 1.1 | 60 |
| 71 | Postoperative Management in Patients with Pheochromocytoma and Paraganglioma. <i>Cancers</i> , 2019, 11, 936. | 1.7 | 25 |
| 72 | Current experts'™ views on precision nuclear medicine imaging of pheochromocytoma and paraganglioma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 2223-2224. | 3.3 | 6 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 73 | Medullary Thyroid Carcinoma: An Update on Imaging. <i>Journal of Thyroid Research</i> , 2019, 2019, 1-17. | 0.5 | 36 |
| 74 | European Association of Nuclear Medicine Practice Guideline/Society of Nuclear Medicine and Molecular Imaging Procedure Standard 2019 for radionuclide imaging of pheochromocytoma and paraganglioma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 2112-2137. | 3.3 | 208 |
| 75 | Adipocyte β^2 -arrestin-2 is essential for maintaining whole body glucose and energy homeostasis. <i>Nature Communications</i> , 2019, 10, 2936. | 5.8 | 43 |
| 76 | Current Management of Pheochromocytoma/Paraganglioma: A Guide for the Practicing Clinician in the Era of Precision Medicine. <i>Cancers</i> , 2019, 11, 1505. | 1.7 | 120 |
| 77 | Pseudopheochromocytoma. <i>Endocrinology and Metabolism Clinics of North America</i> , 2019, 48, 751-764. | 1.2 | 9 |
| 78 | Coley's immunotherapy revived: Innate immunity as a link in priming cancer cells for an attack by adaptive immunity. <i>Seminars in Oncology</i> , 2019, 46, 385-392. | 0.8 | 11 |
| 79 | Tumor multifocality with vagus nerve involvement as a phenotypic marker of <i>SDHD</i> mutation in patients with head and neck paragangliomas: A ¹⁸ F-DOPA PET/CT study. <i>Head and Neck</i> , 2019, 41, 1565-1571. | 0.9 | 4 |
| 80 | Exploring the link between tumour metabolism and succinate dehydrogenase deficiency: A ¹⁸ F-DOPA PET/CT study in head and neck paragangliomas. <i>Clinical Endocrinology</i> , 2019, 91, 879-884. | 1.2 | 3 |
| 81 | Synergistic Highly Potent Targeted Drug Combinations in Different Pheochromocytoma Models Including Human Tumor Cultures. <i>Endocrinology</i> , 2019, 160, 2600-2617. | 1.4 | 24 |
| 82 | Optimizing Genetic Workup in Pheochromocytoma and Paraganglioma by Integrating Diagnostic and Research Approaches. <i>Cancers</i> , 2019, 11, 809. | 1.7 | 23 |
| 83 | More on Ivabradine in Tachycardia with Paraganglioma. <i>New England Journal of Medicine</i> , 2019, 380, 2590-2590. | 13.9 | 0 |
| 84 | MicroRNA-210 May Be a Preoperative Biomarker of Malignant Pheochromocytomas and Paragangliomas. <i>Journal of Surgical Research</i> , 2019, 243, 1-7. | 0.8 | 11 |
| 85 | Chiari Malformation Type 1 in EPAS1-Associated Syndrome. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2819. | 1.8 | 8 |
| 86 | A Transgenic Mouse Model of Pacak-Zhuang Syndrome with An Epas1 Gain-of-Function Mutation. <i>Cancers</i> , 2019, 11, 667. | 1.7 | 22 |
| 87 | Gallbladder Paraganglioma Associated with SDHD Mutation: a Potential Pitfall on ¹⁸ F-FDOPA PET Imaging. <i>Nuclear Medicine and Molecular Imaging</i> , 2019, 53, 144-147. | 0.6 | 6 |
| 88 | Impact of Extrinsic and Intrinsic Hypoxia on Catecholamine Biosynthesis in Absence or Presence of Hif2 α in Pheochromocytoma Cells. <i>Cancers</i> , 2019, 11, 594. | 1.7 | 24 |
| 89 | The Significant Reduction or Complete Eradication of Subcutaneous and Metastatic Lesions in a Pheochromocytoma Mouse Model after Immunotherapy Using Mannan-BAM, TLR Ligands, and Anti-CD40. <i>Cancers</i> , 2019, 11, 654. | 1.7 | 21 |
| 90 | A Previously Unrecognized Monocytic Component of Pheochromocytoma and Paraganglioma. <i>Endocrine Pathology</i> , 2019, 30, 90-95. | 5.2 | 14 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 91 | Gs β deficiency in the dorsomedial hypothalamus leads to obesity, hyperphagia, and reduced thermogenesis associated with impaired leptin signaling. <i>Molecular Metabolism</i> , 2019, 25, 142-153. | 3.0 | 8 |
| 92 | A Necessity, not a Second Thought: Pre-Operative Alpha-Adrenoceptor Blockade in Pheochromocytoma Patients. <i>Endocrine Practice</i> , 2019, 25, 200-201. | 1.1 | 1 |
| 93 | Clinical, Diagnostic, and Treatment Characteristics of SDHA-Related Metastatic Pheochromocytoma and Paraganglioma. <i>Frontiers in Oncology</i> , 2019, 9, 53. | 1.3 | 39 |
| 94 | Ivabradine in Catecholamine-Induced Tachycardia in a Patient with Paraganglioma. <i>New England Journal of Medicine</i> , 2019, 380, 1284-1286. | 13.9 | 9 |
| 95 | Eruption of Metastatic Paraganglioma After Successful Therapy with ¹⁷⁷ Lu/90Y-DOTATOC and ¹⁷⁷ Lu-DOTATATE. <i>Nuclear Medicine and Molecular Imaging</i> , 2019, 53, 223-230. | 0.6 | 9 |
| 96 | Pheochromocytomas and Paragangliomas: From Genetic Diversity to Targeted Therapies. <i>Cancers</i> , 2019, 11, 436. | 1.7 | 33 |
| 97 | Catecholamine-Induced Cardiomyopathy in Pheochromocytoma: How to Manage a Rare Complication in a Rare Disease?. <i>Hormone and Metabolic Research</i> , 2019, 51, 458-469. | 0.7 | 51 |
| 98 | Reactivation of Dihydroorotate Dehydrogenase-Driven Pyrimidine Biosynthesis Restores Tumor Growth of Respiration-Deficient Cancer Cells. <i>Cell Metabolism</i> , 2019, 29, 399-416.e10. | 7.2 | 190 |
| 99 | Nonmosaic somatic <i>HIF2A</i> mutations associated with late onset polycythemia in paraganglioma syndrome: Newly recognized subclass of polycythemia in paraganglioma syndrome. <i>Cancer</i> , 2019, 125, 1258-1266. | 2.0 | 11 |
| 100 | The 3PAs: An Update on the Association of Pheochromocytomas, Paragangliomas, and Pituitary Tumors. <i>Hormone and Metabolic Research</i> , 2019, 51, 419-436. | 0.7 | 22 |
| 101 | Metastatic Pheochromocytoma: Spinning Towards More Promising Treatment Options. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2019, 127, 117-128. | 0.6 | 40 |
| 102 | Why Take the Risk? We Only Live Once: The Dangers Associated with Neglecting a Pre-Operative Alpha Adrenoceptor Blockade in Pheochromocytoma Patients. <i>Endocrine Practice</i> , 2019, 25, 106-108. | 1.1 | 14 |
| 103 | Radioguided Surgery With Gallium 68 Dotatate for Patients With Neuroendocrine Tumors. <i>JAMA Surgery</i> , 2019, 154, 40. | 2.2 | 34 |
| 104 | Preoperative ¹⁸ F-FDG PET/CT in Pheochromocytomas and Paragangliomas Allows for Precision Surgery. <i>Annals of Surgery</i> , 2019, 269, 741-747. | 2.1 | 15 |
| 105 | Diagnostic Investigation of Lesions Associated with Succinate Dehydrogenase Defects. <i>Hormone and Metabolic Research</i> , 2019, 51, 414-418. | 0.7 | 5 |
| 106 | A high rate of modestly elevated plasma normetanephrine in a population referred for suspected PPGL when measured in a seated position. <i>European Journal of Endocrinology</i> , 2019, 181, 301-309. | 1.9 | 25 |
| 107 | Genotype-phenotype correlations in pheochromocytoma and paraganglioma: a systematic review and individual patient meta-analysis. <i>Endocrine-Related Cancer</i> , 2019, 26, 539-550. | 1.6 | 87 |
| 108 | Molecular imaging and radionuclide therapy of pheochromocytoma and paraganglioma in the era of genomic characterization of disease subgroups. <i>Endocrine-Related Cancer</i> , 2019, 26, R627-R652. | 1.6 | 72 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 109 | Characteristic CT features of pheochromocytomas - probability model calculation tool based on a multicentric study. Biomedical Papers of the Medical Faculty of the University Palacký; Olomouc, Czechoslovakia, 2019, 163, 212-219. | 0.2 | 15 |
| 110 | 18F-FDOPA PET/CT Imaging of MAX-Related Pheochromocytoma. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 1574-1582. | 1.8 | 27 |
| 111 | Continued Tumor Reduction of Metastatic Pheochromocytoma/Paraganglioma Harboring Succinate Dehydrogenase Subunit B Mutations with Cyclical Chemotherapy. Cellular and Molecular Neurobiology, 2018, 38, 1099-1106. | 1.7 | 27 |
| 112 | Targeting NAD ⁺ /PARP DNA Repair Pathway as a Novel Therapeutic Approach to SDHB-Mutated Cluster I Pheochromocytoma and Paraganglioma. Clinical Cancer Research, 2018, 24, 3423-3432. | 3.2 | 57 |
| 113 | Molecular imaging and theranostic approaches in pheochromocytoma and paraganglioma. Cell and Tissue Research, 2018, 372, 393-401. | 1.5 | 37 |
| 114 | Successful induction therapy with sequential CVD followed by high-dose lanreotide in for metastatic SDHB paraganglioma: Case report. Journal of Clinical and Translational Endocrinology: Case Reports, 2018, 7, 8-13. | 0.4 | 3 |
| 115 | Genomic Landscape of Pheochromocytoma and Paraganglioma. Trends in Cancer, 2018, 4, 6-9. | 3.8 | 71 |
| 116 | Prognostic Utility of Total 68Ga-DOTATATE-Avid Tumor Volume in Patients With Neuroendocrine Tumors. Gastroenterology, 2018, 154, 998-1008.e1. | 0.6 | 62 |
| 117 | Deletion of the von Hippel-Lindau Gene in Hemangioblasts Causes Hemangioblastoma-like Lesions in Murine Retina. Cancer Research, 2018, 78, 1266-1274. | 0.4 | 16 |
| 118 | Successful Second-Line Metronomic Temozolomide in Metastatic Paraganglioma: Case Reports and Review of the Literature. Clinical Medicine Insights: Oncology, 2018, 12, 117955491876336. | 0.6 | 27 |
| 119 | A novel splicing site IRP1 somatic mutation in a patient with pheochromocytoma and JAK2V617F positive polycythemia vera: a case report. BMC Cancer, 2018, 18, 286. | 1.1 | 15 |
| 120 | Pheochromocytoma/Paraganglioma: Update on Diagnosis and Management. Contemporary Endocrinology, 2018, , 261-310. | 0.3 | 2 |
| 121 | Quantitative 18F-DOPA PET/CT in pheochromocytoma: the relationship between tumor secretion and its biochemical phenotype. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 278-282. | 3.3 | 28 |
| 122 | Superiority of 68Ga-DOTATATE over 18F-FDG and anatomic imaging in the detection of succinate dehydrogenase mutation (SDHx)-related pheochromocytoma and paraganglioma in the pediatric population. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 787-797. | 3.3 | 64 |
| 123 | New Challenges in Nuclear Endocrinology. Journal of Nuclear Medicine, 2018, 59, 573-574. | 2.8 | 0 |
| 124 | Preoperative genetic testing in pheochromocytomas and paragangliomas influences the surgical approach and the extent of adrenal surgery. Surgery, 2018, 163, 191-196. | 1.0 | 32 |
| 125 | Blood collection in unstressed, conscious, and freely moving mice through implantation of catheters in the jugular vein: a new simplified protocol. Physiological Reports, 2018, 6, e13904. | 0.7 | 10 |
| 126 | RNA-Sequencing Analysis of Adrenocortical Carcinoma, Pheochromocytoma and Paraganglioma from a Pan-Cancer Perspective. Cancers, 2018, 10, 518. | 1.7 | 10 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 127 | New insights on the pathogenesis of paraganglioma and pheochromocytoma. F1000Research, 2018, 7, 1500. | 0.8 | 17 |
| 128 | SDHD Gene Mutations: Looking Beyond Head and Neck Tumors. AACE Clinical Case Reports, 2018, 4, 186-190. | 0.4 | 0 |
| 129 | Primary fibroblast co-culture stimulates growth and metabolism in Sdhb-impaired mouse pheochromocytoma MTT cells. Cell and Tissue Research, 2018, 374, 473-485. | 1.5 | 23 |
| 130 | Prospective evaluation of ^{68}Ga -DOTATATE PET/CT in limited disease neuroendocrine tumours and/or elevated serum neuroendocrine biomarkers. Clinical Endocrinology, 2018, 89, 155-163. | 1.2 | 11 |
| 131 | Molecular evaluation of a sporadic paraganglioma with concurrent IDH1 and ATRX mutations. Endocrine, 2018, 61, 216-223. | 1.1 | 7 |
| 132 | A Clinical Roadmap to Investigate the Genetic Basis of Pediatric Pheochromocytoma: Which Genes Should Physicians Think About?. International Journal of Endocrinology, 2018, 2018, 1-14. | 0.6 | 11 |
| 133 | Role of MDH2 pathogenic variant in pheochromocytoma and paraganglioma patients. Genetics in Medicine, 2018, 20, 1652-1662. | 1.1 | 45 |
| 134 | Update of Pheochromocytoma Syndromes: Genetics, Biochemical Evaluation, and Imaging. Frontiers in Endocrinology, 2018, 9, 515. | 1.5 | 82 |
| 135 | Mathematical modeling of disease dynamics in SDHB- and SDHD-related paraganglioma: Further step in understanding hereditary tumor differences and future therapeutic strategies. PLoS ONE, 2018, 13, e0201303. | 1.1 | 4 |
| 136 | The role of GSK3 and its reversal with GSK3 antagonism in everolimus resistance. Endocrine-Related Cancer, 2018, 25, 893-908. | 1.6 | 24 |
| 137 | Alternative assembly of respiratory complex II connects energy stress to metabolic checkpoints. Nature Communications, 2018, 9, 2221. | 5.8 | 44 |
| 138 | Leptomeningeal dissemination of a low-grade lumbar paraganglioma: case report. Journal of Neurosurgery: Spine, 2017, 26, 501-506. | 0.9 | 10 |
| 139 | Comprehensive Molecular Characterization of Pheochromocytoma and Paraganglioma. Cancer Cell, 2017, 31, 181-193. | 7.7 | 532 |
| 140 | Radionuclide Imaging of Head and Neck Paragangliomas. , 2017, , 269-294. | | 0 |
| 141 | Implications of SDHB genetic testing in patients with sporadic pheochromocytoma. Langenbeck's Archives of Surgery, 2017, 402, 787-798. | 0.8 | 4 |
| 142 | Surgical Management of Wild-Type Gastrointestinal Stromal Tumors: A Report From the National Institutes of Health Pediatric and Wildtype GIST Clinic. Journal of Clinical Oncology, 2017, 35, 523-528. | 0.8 | 58 |
| 143 | Emerging role of dopamine in neovascularization of pheochromocytoma and paraganglioma. FASEB Journal, 2017, 31, 2226-2240. | 0.2 | 12 |
| 144 | PET Imaging for Endocrine Malignancies: From Woe to Go. Journal of Nuclear Medicine, 2017, 58, 878-880. | 2.8 | 2 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 145 | Mitochondrial Complex II: At the Crossroads. Trends in Biochemical Sciences, 2017, 42, 312-325. | 3.7 | 192 |
| 146 | Paraganglioma of the organ of Zuckerkandl associated with a somatic HIF2 β mutation: A case report. Oncology Letters, 2017, 13, 1083-1086. | 0.8 | 4 |
| 147 | Accuracy of recommended sampling and assay methods for the determination of plasma-free and urinary fractionated metanephrines in the diagnosis of pheochromocytoma and paraganglioma: a systematic review. Endocrine, 2017, 56, 495-503. | 1.1 | 79 |
| 148 | Characteristics of Pediatric vs Adult Pheochromocytomas and Paragangliomas. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 1122-1132. | 1.8 | 120 |
| 149 | ¹⁸ F-fluorodihydroxyphenylalanine PET/CT in pheochromocytoma and paraganglioma: relation to genotype and amino acid transport system L. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 812-821. | 3.3 | 20 |
| 150 | The Evolving Role of Succinate in Tumor Metabolism: An ¹⁸ F-FDG-Based Study. Journal of Nuclear Medicine, 2017, 58, 1749-1755. | 2.8 | 27 |
| 151 | SDHB-related pheochromocytoma and paraganglioma penetrance and genotype-phenotype correlations. Journal of Cancer Research and Clinical Oncology, 2017, 143, 1421-1435. | 1.2 | 63 |
| 152 | Functional Imaging Signature of Patients Presenting with Polycythemia/Paraganglioma Syndromes. Journal of Nuclear Medicine, 2017, 58, 1236-1242. | 2.8 | 29 |
| 153 | Precision Medicine in Adrenal Disorders: the Next Generation. Endocrine Practice, 2017, 23, 672-679. | 1.1 | 3 |
| 154 | Precision Medicine: An Update on Genotype/Biochemical Phenotype Relationships in Pheochromocytoma/Paraganglioma Patients. Endocrine Practice, 2017, 23, 690-704. | 1.1 | 58 |
| 155 | Association between neuroendocrine tumors biomarkers and primary tumor site and disease type based on total ⁶⁸ Ga-DOTATATE-Avid tumor volume measurements. European Journal of Endocrinology, 2017, 176, 575-582. | 1.9 | 38 |
| 156 | Radionuclide Imaging of Chromaffin Cell Tumors. , 2017, , 295-319. | | 0 |
| 157 | HIF-2alpha: Achilles' heel of pseudohypoxic subtype paraganglioma and other related conditions. European Journal of Cancer, 2017, 86, 1-4. | 1.3 | 16 |
| 158 | The microenvironment induces collective migration in SDHB-silenced mouse pheochromocytoma spheroids. Endocrine-Related Cancer, 2017, 24, 555-564. | 1.6 | 26 |
| 159 | New Insights into the Nuclear Imaging Phenotypes of Cluster 1 Pheochromocytoma and Paraganglioma. Trends in Endocrinology and Metabolism, 2017, 28, 807-817. | 3.1 | 34 |
| 160 | Metanephrines for Evaluating Palpitations and Flushing. JAMA - Journal of the American Medical Association, 2017, 318, 385. | 3.8 | 11 |
| 161 | Mapping of human brown adipose tissue in lean and obese young men. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 8649-8654. | 3.3 | 370 |
| 162 | Relevant Discordance Between ⁶⁸ Ga-DOTATATE and ⁶⁸ Ga-DOTANOC in SDHB-Related Metastatic Paraganglioma. Clinical Nuclear Medicine, 2017, 42, 211-213. | 0.7 | 3 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 163 | New Perspectives on Pheochromocytoma and Paraganglioma: Toward a Molecular Classification. <i>Endocrine Reviews</i> , 2017, 38, 489-515. | 8.9 | 241 |
| 164 | Recent advances in the imaging of pheochromocytomas and paragangliomas. <i>International Journal of Endocrine Oncology</i> , 2017, 4, 137-144. | 0.4 | 0 |
| 165 | PheoSeq. <i>Journal of Molecular Diagnostics</i> , 2017, 19, 575-588. | 1.2 | 63 |
| 166 | Pathological and Genetic Characterization of Bilateral Adrenomedullary Hyperplasia in a Patient with Germline MAX Mutation. <i>Endocrine Pathology</i> , 2017, 28, 302-307. | 5.2 | 25 |
| 167 | SDHB mutation status and tumor size but not tumor grade are important predictors of clinical outcome in pheochromocytoma and abdominal paraganglioma. <i>Surgery</i> , 2017, 161, 230-239. | 1.0 | 60 |
| 168 | Management of Pheochromocytoma and Paraganglioma. , 2017, , 179-206. | | 0 |
| 169 | Reply: 68Ga-DOTATATE PET/CT Versus MRI: Why the Comparison of 68Ga-DOTATATE PET/CT to an Appropriate MRI Protocol Is Essential. <i>Journal of Nuclear Medicine</i> , 2017, 58, 185-185. | 2.8 | 3 |
| 170 | Imaging Modalities for Pheochromocytoma and Paraganglioma. , 2017, , 125-138. | | 0 |
| 171 | Pathology of Human Pheochromocytoma and Paraganglioma Xenografts in NSG Mice. <i>Endocrine Pathology</i> , 2017, 28, 2-6. | 5.2 | 19 |
| 172 | Pediatric patients with pheochromocytoma and paraganglioma should have routine preoperative genetic testing for common susceptibility genes in addition to imaging to detect extra-adrenal and metastatic tumors. <i>Surgery</i> , 2017, 161, 220-227. | 1.0 | 47 |
| 173 | Bortezomib Alone and in Combination With Salinosporamid A Induces Apoptosis and Promotes Pheochromocytoma Cell Death In Vitro and in Female Nude Mice. <i>Endocrinology</i> , 2017, 158, 3097-3108. | 1.4 | 10 |
| 174 | Anthracyclines suppress pheochromocytoma cell characteristics, including metastasis, through inhibition of the hypoxia signaling pathway. <i>Oncotarget</i> , 2017, 8, 22313-22324. | 0.8 | 29 |
| 175 | Cardiometabolic risk factors and health behaviors in family caregivers. <i>PLoS ONE</i> , 2017, 12, e0176408. | 1.1 | 10 |
| 176 | Vorinostat suppresses hypoxia signaling by modulating nuclear translocation of hypoxia inducible factor 1 alpha. <i>Oncotarget</i> , 2017, 8, 56110-56125. | 0.8 | 64 |
| 177 | Uncommon spreading of primary malignant paraganglioma in a patient with SDHB mutation. <i>Case Reports in Internal Medicine</i> , 2016, 4, 63. | 0.0 | 0 |
| 178 | Total 18F-FDG PET/CT Metabolic Tumor Volume Is Associated With Postoperative Biochemical Response in Patients With Metastatic Pheochromocytomas and Paragangliomas. <i>Annals of Surgery</i> , 2016, 263, 582-587. | 2.1 | 10 |
| 179 | 18F-DOPA: the versatile radiopharmaceutical. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 1187-1189. | 3.3 | 15 |
| 180 | Endocrine tumors associated with the vagus nerve. <i>Endocrine-Related Cancer</i> , 2016, 23, R371-R379. | 1.6 | 9 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 181 | Hypoxia-Inducible Factor 2Î± Mutation-Related Paragangliomas Classify as Discrete Pseudohypoxic Subcluster. <i>Neoplasia</i> , 2016, 18, 567-576. | 2.3 | 16 |
| 182 | Novel insights into the polycythemiaâ€“paragangliomaâ€“somatostatinoma syndrome. <i>Endocrine-Related Cancer</i> , 2016, 23, 899-908. | 1.6 | 62 |
| 183 | HIF2A gain-of-function mutations detected in duodenal gangliocytic paraganglioma. <i>Endocrine-Related Cancer</i> , 2016, 23, L13-L16. | 1.6 | 20 |
| 184 | The Author's Reply: inappropriate adrenoreceptor blockade prior to pheochromocytoma removal â€“ â€“A timely reappraisalâ€™. <i>Clinical Endocrinology</i> , 2016, 85, 990-991. | 1.2 | 0 |
| 185 | Nuclear Medicine in Cancer Theranostics: Beyond the Target. <i>Journal of Nuclear Medicine</i> , 2016, 57, 1659-1660. | 2.8 | 14 |
| 186 | Molecular Imaging of Gastroenteropancreatic Neuroendocrine Tumors: Current Status and Future Directions. <i>Journal of Nuclear Medicine</i> , 2016, 57, 1949-1956. | 2.8 | 119 |
| 187 | Pheochromocytoma: The First Metabolic Endocrine Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 5001-5011. | 3.2 | 59 |
| 188 | AN AGGRESSIVE TEMPORAL BONE SDHC PARAGANGLIOMA ASSOCIATED WITH INCREASED HIF-2Î± SIGNALING. <i>Endocrine Practice</i> , 2016, 22, 190-195. | 1.1 | 6 |
| 189 | Functional Imaging Experience in a Germline Fumarate Hydratase Mutationâ€“Positive Patient With Pheochromocytoma and Paraganglioma. <i>AACE Clinical Case Reports</i> , 2016, 2, e176-e181. | 0.4 | 9 |
| 190 | Characteristics And Outcomes Of Metastatic Sdhb And Sporadic Pheochromocytoma/Paraganglioma: An National Institutes Of Health Study. <i>Endocrine Practice</i> , 2016, 22, 302-314. | 1.1 | 110 |
| 191 | Are patients with hormonally functional phaeochromocytoma and paraganglioma initially receiving a proper adrenoceptor blockade? A retrospective cohort study. <i>Clinical Endocrinology</i> , 2016, 85, 62-69. | 1.2 | 14 |
| 192 | Rapidly Growing Chest Wall Mass in a Case of Sporadic Metastatic Paraganglioma. <i>Clinical Nuclear Medicine</i> , 2016, 41, 399-400. | 0.7 | 2 |
| 193 | Radiopharmaceuticals in paraganglioma imaging: too many members on board?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 391-393. | 3.3 | 6 |
| 194 | PET/CT comparing 68Ga-DOTATATE and other radiopharmaceuticals and in comparison with CT/MRI for the localization of sporadic metastatic pheochromocytoma and paraganglioma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 1784-1791. | 3.3 | 138 |
| 195 | Molecular Subtypes of <i>KIT/PDGFR</i> Wild-Type Gastrointestinal Stromal Tumors. <i>JAMA Oncology</i> , 2016, 2, 922. | 3.4 | 291 |
| 196 | Somatic gain-of-function HIF2A mutations in sporadic central nervous system hemangioblastomas. <i>Journal of Neuro-Oncology</i> , 2016, 126, 473-481. | 1.4 | 18 |
| 197 | InÂvivo detection of catecholamines byÂmagnetic resonance spectroscopy: AÂpotential specific biomarker for the diagnosis of pheochromocytoma. <i>Surgery</i> , 2016, 159, 1231-1233. | 1.0 | 10 |
| 198 | Documenting stress in caregivers of transplantation patients: initial evidence of HPA dysregulation. <i>Stress</i> , 2016, 19, 175-184. | 0.8 | 31 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 199 | Mass spectrometric quantification of salivary metanephrines—A study in healthy subjects. <i>Clinical Biochemistry</i> , 2016, 49, 983-988. | 0.8 | 10 |
| 200 | Prospective comparison of ⁶⁸ Ga-DOTATATE and ¹⁸ F-FDOPA PET/CT in patients with various pheochromocytomas and paragangliomas with emphasis on sporadic cases. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 1248-1257. | 3.3 | 96 |
| 201 | Prospective Study of ⁶⁸ Ga-DOTATATE Positron Emission Tomography/Computed Tomography for Detecting Gastro-Entero-Pancreatic Neuroendocrine Tumors and Unknown Primary Sites. <i>Journal of Clinical Oncology</i> , 2016, 34, 588-596. | 0.8 | 287 |
| 202 | ⁶⁸ Ga-DOTATATE PET/CT in the Localization of Head and Neck Paragangliomas Compared with Other Functional Imaging Modalities and CT/MRI. <i>Journal of Nuclear Medicine</i> , 2016, 57, 186-191. | 2.8 | 148 |
| 203 | Determination of the unmetabolised ¹⁸ F-FDG fraction by using an extension of simplified kinetic analysis method: clinical evaluation in paragangliomas. <i>Medical and Biological Engineering and Computing</i> , 2016, 54, 103-111. | 1.6 | 9 |
| 204 | Carney triad can be (rarely) associated with germline succinate dehydrogenase defects. <i>European Journal of Human Genetics</i> , 2016, 24, 569-573. | 1.4 | 57 |
| 205 | Hypoxia potentiates the cytotoxic effect of piperlongumine in pheochromocytoma models. <i>Oncotarget</i> , 2016, 7, 40531-40545. | 0.8 | 10 |
| 206 | Pheochromocytoma Resection: The Rule of Surgical Divergence. <i>ACE Clinical Case Reports</i> , 2016, 2, e78-e79. | 0.4 | 2 |
| 207 | Somatic mosaicism of EPAS1 mutations in the syndrome of paraganglioma and somatostatinoma associated with polycythemia. <i>Human Genome Variation</i> , 2015, 2, 15053. | 0.4 | 26 |
| 208 | Multidisciplinary management of locally advanced and widely metastatic paraganglioma in a patient with life-threatening compressive symptoms. <i>Head and Neck</i> , 2015, 37, E205-8. | 0.9 | 2 |
| 209 | Urinary Bladder Paragangliomas. <i>American Journal of Surgical Pathology</i> , 2015, 39, 1488-1492. | 2.1 | 20 |
| 210 | SDHB/SDHA immunohistochemistry in pheochromocytomas and paragangliomas: a multicenter interobserver variation analysis using virtual microscopy: a Multinational Study of the European Network for the Study of Adrenal Tumors (ENS@T). <i>Modern Pathology</i> , 2015, 28, 807-821. | 2.9 | 176 |
| 211 | Lack of utility of SDHB mutation testing in adrenergic metastatic pheochromocytoma. <i>European Journal of Endocrinology</i> , 2015, 172, 89-95. | 1.9 | 17 |
| 212 | Pheochromocytoma Screening Initiation and Frequency in von Hippel-Lindau Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 4498-4504. | 1.8 | 60 |
| 213 | Metabolome Profiling by HRMAS NMR Spectroscopy of Pheochromocytomas and Paragangliomas Detects SDH Deficiency: Clinical and Pathophysiological Implications. <i>Neoplasia</i> , 2015, 17, 55-65. | 2.3 | 60 |
| 214 | Pituitary Adenoma With Paraganglioma/Pheochromocytoma (3PAs) and Succinate Dehydrogenase Defects in Humans and Mice. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, E710-E719. | 1.8 | 121 |
| 215 | Results of ⁶⁸ Gallium-DOTATATE PET/CT Scanning in Patients with Multiple Endocrine Neoplasia Type 1. <i>Journal of the American College of Surgeons</i> , 2015, 221, 509-517. | 0.2 | 72 |
| 216 | Pheochromocytoma and Paraganglioma Syndromes. , 2015, , 449-454. | | 2 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 217 | Pheochromocytoma: Gasping for Air. <i>Hormones and Cancer</i> , 2015, 6, 191-205. | 4.9 | 26 |
| 218 | Magnetic resonance spectroscopy of paragangliomas: new insights into in vivo metabolomics. <i>Endocrine-Related Cancer</i> , 2015, 22, M1-M8. | 1.6 | 34 |
| 219 | Association of urinary bladder paragangliomas with germline mutations in the SDHB and VHL genes. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 167.e13-167.e20. | 0.8 | 24 |
| 220 | Preoperative Imaging Features are Associated with Surgical Complications Following Carotid Body Tumor Resection. <i>World Journal of Surgery</i> , 2015, 39, 2084-2089. | 0.8 | 15 |
| 221 | Succinate Dehydrogenase Gene Mutations in Cardiac Paragangliomas. <i>American Journal of Cardiology</i> , 2015, 115, 1753-1759. | 0.7 | 30 |
| 222 | Superiority of [68Ga]-DOTATATE PET/CT to Other Functional Imaging Modalities in the Localization of <i><i>SDHB</i>-Associated Metastatic Pheochromocytoma and Paraganglioma</i> . <i>Clinical Cancer Research</i> , 2015, 21, 3888-3895. | 3.2 | 223 |
| 223 | Pheochromocytoma and Paraganglioma. <i>Endocrine Practice</i> , 2015, 21, 406-412. | 1.1 | 54 |
| 224 | 18F-FLT PET/CT in the Evaluation of Pheochromocytomas and Paragangliomas: A Pilot Study. <i>Journal of Nuclear Medicine</i> , 2015, 56, 1849-1854. | 2.8 | 4 |
| 225 | Carney triad, SDH-deficient tumors, and <i>Sdhb+/-</i> mice share abnormal mitochondria. <i>Endocrine-Related Cancer</i> , 2015, 22, 345-352. | 1.6 | 23 |
| 226 | Pendrin localizes to the adrenal medulla and modulates catecholamine release. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2015, 309, E534-E545. | 1.8 | 23 |
| 227 | Application and Dosimetric Requirements for Gallium-68 labeled Somatostatin Analogues in Targeted Radionuclide Therapy for Gastroenteropancreatic Neuroendocrine Tumors. <i>PET Clinics</i> , 2015, 10, 477-486. | 1.5 | 14 |
| 228 | Inhibitory Effect of the Noncamptothecin Topoisomerase I Inhibitor LMP-400 on Female Mice Models and Human Pheochromocytoma Cells. <i>Endocrinology</i> , 2015, 156, 4094-4104. | 1.4 | 12 |
| 229 | 15 YEARS OF PARAGANGLIOMA: Imaging and imaging-based treatment of pheochromocytoma and paraganglioma. <i>Endocrine-Related Cancer</i> , 2015, 22, T135-T145. | 1.6 | 84 |
| 230 | Germ-line PHD1 and PHD2 mutations detected in patients with pheochromocytoma/paraganglioma-polycythemia. <i>Journal of Molecular Medicine</i> , 2015, 93, 93-104. | 1.7 | 118 |
| 231 | Potential therapeutic target for malignant paragangliomas: ATP synthase on the surface of paraganglioma cells. <i>American Journal of Cancer Research</i> , 2015, 5, 1558-70. | 1.4 | 10 |
| 232 | High-Throughput Screening for the Identification of New Therapeutic Options for Metastatic Pheochromocytoma and Paraganglioma. <i>PLoS ONE</i> , 2014, 9, e90458. | 1.1 | 9 |
| 233 | Cytocidal Activities of Topoisomerase 1 Inhibitors and 5-Azacytidine against Pheochromocytoma/Paraganglioma Cells in Primary Human Tumor Cultures and Mouse Cell Lines. <i>PLoS ONE</i> , 2014, 9, e87807. | 1.1 | 14 |
| 234 | ZNF367 Inhibits Cancer Progression and Is Targeted by miR-195. <i>PLoS ONE</i> , 2014, 9, e101423. | 1.1 | 36 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 235 | Krebs Cycle Metabolite Profiling for Identification and Stratification of Pheochromocytomas/Parangliomas due to Succinate Dehydrogenase Deficiency. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 3903-3911. | 1.8 | 111 |
| 236 | Protocol for the Examination of Specimens From Patients With Pheochromocytomas and Extra-Adrenal Parangliomas. <i>Archives of Pathology and Laboratory Medicine</i> , 2014, 138, 182-188. | 1.2 | 52 |
| 237 | External Beam Radiation Therapy in Treatment of Malignant Pheochromocytoma and Paranglioma. <i>Frontiers in Oncology</i> , 2014, 4, 166. | 1.3 | 51 |
| 238 | Succinate-to-Fumarate Ratio as a New Metabolic Marker to Detect the Presence of SDHB/D-related Paranglioma: Initial Experimental and Ex Vivo Findings. <i>Endocrinology</i> , 2014, 155, 27-32. | 1.4 | 63 |
| 239 | Combination of 13-Cis Retinoic Acid and Lovastatin: Marked Antitumor Potential In Vivo in a Pheochromocytoma Allograft Model in Female Athymic Nude Mice. <i>Endocrinology</i> , 2014, 155, 2377-2390. | 1.4 | 15 |
| 240 | Counseling patients with succinate dehydrogenase subunit defects: genetics, preventive guidelines, and dealing with uncertainty. <i>Journal of Pediatric Endocrinology and Metabolism</i> , 2014, 27, 837-44. | 0.4 | 12 |
| 241 | ¹⁸ F-FDG PET/CT as a predictor of hereditary head and neck paragangliomas. <i>European Journal of Clinical Investigation</i> , 2014, 44, 325-332. | 1.7 | 30 |
| 242 | Clinical utility of chromogranin A in SDHx-related paragangliomas. <i>European Journal of Clinical Investigation</i> , 2014, 44, 365-371. | 1.7 | 40 |
| 243 | Diagnosis and preoperative imaging of multiple endocrine neoplasia type 2: current status and future directions. <i>Clinical Endocrinology</i> , 2014, 81, 317-328. | 1.2 | 24 |
| 244 | Integrated Whole-Body PET/MRI With 18F-FDG, 18F-FDOPA, and 18F-FDA in Parangliomas in Comparison With PET/CT. <i>Clinical Nuclear Medicine</i> , 2014, 39, 243-250. | 0.7 | 19 |
| 245 | Current views on cell metabolism in SDHx-related pheochromocytoma and paraganglioma. <i>Endocrine-Related Cancer</i> , 2014, 21, R261-R277. | 1.6 | 31 |
| 246 | Monoamine Oxidase B Prompts Mitochondrial and Cardiac Dysfunction in Pressure Overloaded Hearts. <i>Antioxidants and Redox Signaling</i> , 2014, 20, 267-280. | 2.5 | 135 |
| 247 | The Adrenal Medulla and Extra-adrenal Paranglia: Then and Now. <i>Endocrine Pathology</i> , 2014, 25, 49-58. | 5.2 | 39 |
| 248 | The Genetic Basis of Pheochromocytoma and Paranglioma: Implications for Management. <i>Urology</i> , 2014, 83, 1225-1232. | 0.5 | 40 |
| 249 | Irisin and FGF21 Are Cold-Induced Endocrine Activators of Brown Fat Function in Humans. <i>Cell Metabolism</i> , 2014, 19, 302-309. | 7.2 | 643 |
| 250 | Familial pheochromocytomas and paragangliomas. <i>Molecular and Cellular Endocrinology</i> , 2014, 386, 92-100. | 1.6 | 47 |
| 251 | Genetics, Diagnosis, and Management of Medullary Thyroid Carcinoma and Pheochromocytoma/Paranglioma. <i>Endocrine Practice</i> , 2014, 20, 176-187. | 1.1 | 14 |
| 252 | Pheochromocytoma and paraganglioma: Diagnosis, genetics, management, and treatment. <i>Current Problems in Cancer</i> , 2014, 38, 7-41. | 1.0 | 163 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 253 | Ocular Manifestations of Hypoxia-Inducible Factor-2 β Paranglioma-Somatostatinoma-Polycythemia Syndrome. <i>Ophthalmology</i> , 2014, 121, 2291-2293. | 2.5 | 23 |
| 254 | Current Approaches and Recent Developments in the Management of Head and Neck Parangliomas. <i>Endocrine Reviews</i> , 2014, 35, 795-819. | 8.9 | 124 |
| 255 | Opposing effects of HIF1 α and HIF2 α on chromaffin cell phenotypic features and tumor cell proliferation: Insights from MYC-associated factor X. <i>International Journal of Cancer</i> , 2014, 135, 2054-2064. | 2.3 | 72 |
| 256 | Correlation Between In Vivo ¹⁸ F-FDG PET and Immunohistochemical Markers of Glucose Uptake and Metabolism in Pheochromocytoma and Paranglioma. <i>Journal of Nuclear Medicine</i> , 2014, 55, 1253-1259. | 2.8 | 67 |
| 257 | Renaissance of 18F-FDG Positron Emission Tomography in the Imaging of Pheochromocytoma/Paranglioma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 2337-2339. | 1.8 | 18 |
| 258 | The size of the primary tumor and age at initial diagnosis are independent predictors of the metastatic behavior and survival of patients with SDHB-related pheochromocytoma and paranglioma: a retrospective cohort study. <i>BMC Cancer</i> , 2014, 14, 523. | 1.1 | 55 |
| 259 | Pheochromocytoma and Paranglioma: An Endocrine Society Clinical Practice Guideline. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 1915-1942. | 1.8 | 2,031 |
| 260 | Association between acute sympathetic response, early onset vasospasm, and delayed vasospasm following spontaneous subarachnoid hemorrhage. <i>Journal of Clinical Neuroscience</i> , 2014, 21, 256-262. | 0.8 | 17 |
| 261 | The Presence of SDHB Mutations Should Modify Surgical Indications for Carotid Body Parangliomas. <i>Annals of Surgery</i> , 2014, 260, 158-162. | 2.1 | 50 |
| 262 | Pheochromocytoma Hypertensive Crisis. , 2014, , 139-147. | | 1 |
| 263 | Anti-Cancer Potential of MAPK Pathway Inhibition in Parangliomas—Effect of Different Statins on Mouse Pheochromocytoma Cells. <i>PLoS ONE</i> , 2014, 9, e97712. | 1.1 | 24 |
| 264 | A novel EPAS1/HIF2A germline mutation in a congenital polycythemia with paranglioma. <i>Journal of Molecular Medicine</i> , 2013, 91, 507-512. | 1.7 | 155 |
| 265 | Double stable isotope ultra performance liquid chromatographic-tandem mass spectrometric quantification of tissue content and activity of phenylethanolamine N-methyltransferase, the crucial enzyme responsible for synthesis of epinephrine. <i>Analytical and Bioanalytical Chemistry</i> , 2013, 405, 1713-1719. | 1.9 | 4 |
| 266 | Landscape of the mitochondrial Hsp90 metabolome in tumours. <i>Nature Communications</i> , 2013, 4, 2139. | 5.8 | 135 |
| 267 | Multitracer PET imaging of bone metastases from paranglioma: peripheral halo of uptake on 18F-FLT PET mismatching with central uptake of 18F-FDOPA, 18F-fluorodopamine, and 18F-FDG. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2013, 40, 1928-1929. | 3.3 | 1 |
| 268 | Association between sympathetic response, neurogenic cardiomyopathy, and venous thromboembolization in patients with primary subarachnoid hemorrhage. <i>Acta Neurochirurgica</i> , 2013, 155, 1501-1510. | 0.9 | 7 |
| 269 | Response after Surgical Resection of Metastatic Pheochromocytoma and Paranglioma: Can Postoperative Biochemical Remission Be Predicted?. <i>Journal of the American College of Surgeons</i> , 2013, 217, 489-496. | 0.2 | 44 |
| 270 | Plasma-free vs deconjugated metanephrines for diagnosis of pheochromocytoma. <i>Clinical Endocrinology</i> , 2013, 79, 476-483. | 1.2 | 15 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 271 | Role of Hypoxia and HIF2 α in Development of the Sympathoadrenal Cell Lineage and Chromaffin Cell Tumors with Distinct Catecholamine Phenotypic Features. <i>Advances in Pharmacology</i> , 2013, 68, 285-317. | 1.2 | 34 |
| 272 | Novel HIF2A mutations disrupt oxygen sensing, leading to polycythemia, paragangliomas, and somatostatinomas. <i>Blood</i> , 2013, 121, 2563-2566. | 0.6 | 87 |
| 273 | Reference intervals for plasma free metanephrines with an age adjustment for normetanephrine for optimized laboratory testing of pheochromocytoma. <i>Annals of Clinical Biochemistry</i> , 2013, 50, 62-69. | 0.8 | 98 |
| 274 | Histone deacetylase inhibitors increase glucocerebrosidase activity in Gaucher disease by modulation of molecular chaperones. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 966-971. | 3.3 | 66 |
| 275 | Genotype and Tumor Locus Determine Expression Profile of Pseudohypoxic Pheochromocytomas and Paragangliomas. <i>Neoplasia</i> , 2013, 15, 435-IN22. | 2.3 | 33 |
| 276 | Current and Future Trends in the Anatomical and Functional Imaging of Head and Neck Paragangliomas. <i>Seminars in Nuclear Medicine</i> , 2013, 43, 462-473. | 2.5 | 23 |
| 277 | Pheochromocytoma: Unmasking the Chameleon. , 2013, , 123-148. | | 3 |
| 278 | Combined Inhibition of mTORC1 and mTORC2 Signaling Pathways Is a Promising Therapeutic Option in Inhibiting Pheochromocytoma Tumor Growth: In Vitro and In Vivo Studies in Female Athymic Nude Mice. <i>Endocrinology</i> , 2013, 154, 646-655. | 1.4 | 41 |
| 279 | First Report of Bilateral Pheochromocytoma in the Clinical Spectrum of <i>HIF2A</i> -Related Polycythemia-Paraganglioma Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, E908-E913. | 1.8 | 54 |
| 280 | Genetics of pheochromocytoma and paraganglioma syndromes. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2013, 20, 186-191. | 1.2 | 51 |
| 281 | Genotype-Specific Abnormalities in Mitochondrial Function Associate with Distinct Profiles of Energy Metabolism and Catecholamine Content in Pheochromocytoma and Paraganglioma. <i>Clinical Cancer Research</i> , 2013, 19, 3787-3795. | 3.2 | 53 |
| 282 | Succinate Dehydrogenase Mutation Underlies Global Epigenomic Divergence in Gastrointestinal Stromal Tumor. <i>Cancer Discovery</i> , 2013, 3, 648-657. | 7.7 | 288 |
| 283 | Commentary. <i>Clinical Chemistry</i> , 2013, 59, 1565-1565. | 1.5 | 0 |
| 284 | New Syndrome of Paraganglioma and Somatostatinoma Associated With Polycythemia. <i>Journal of Clinical Oncology</i> , 2013, 31, 1690-1698. | 0.8 | 129 |
| 285 | Hypoxia-Inducible Factor Signaling in Pheochromocytoma: Turning the Rudder in the Right Direction. <i>Journal of the National Cancer Institute</i> , 2013, 105, 1270-1283. | 3.0 | 146 |
| 286 | Functional characterization of nonmetastatic paraganglioma and pheochromocytoma by ¹⁸ F-FDOPA PET: focus on missed lesions. <i>Clinical Endocrinology</i> , 2013, 79, 170-177. | 1.2 | 49 |
| 287 | Phospho-mTOR is not upregulated in metastatic SDHB paragangliomas. <i>European Journal of Clinical Investigation</i> , 2013, 43, 970-977. | 1.7 | 10 |
| 288 | Targeting Heat Shock Protein 90 for the Treatment of Malignant Pheochromocytoma. <i>PLoS ONE</i> , 2013, 8, e56083. | 1.1 | 23 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 289 | A New Specific Succinate-Glutamate Metabolomic Hallmark in Sdhx-Related Paragangliomas. PLoS ONE, 2013, 8, e80539. | 1.1 | 39 |
| 290 | False-negative 123I-MIBG SPECT is most commonly found in SDHB-related pheochromocytoma or paraganglioma with high frequency to develop metastatic disease. Endocrine-Related Cancer, 2012, 19, 83-93. | 1.6 | 106 |
| 291 | Combined blockade of signalling pathways shows marked anti-tumour potential in phaeochromocytoma cell lines. Journal of Molecular Endocrinology, 2012, 49, 79-96. | 1.1 | 44 |
| 292 | Staging and Functional Characterization of Pheochromocytoma and Paraganglioma by 18F-Fluorodeoxyglucose (18F-FDG) Positron Emission Tomography. Journal of the National Cancer Institute, 2012, 104, 700-708. | 3.0 | 240 |
| 293 | Somatic <i>HIF2A</i> Gain-of-Function Mutations in Paraganglioma with Polycythemia. New England Journal of Medicine, 2012, 367, 922-930. | 13.9 | 338 |
| 294 | <i>MAX</i> Mutations Cause Hereditary and Sporadic Pheochromocytoma and Paraganglioma. Clinical Cancer Research, 2012, 18, 2828-2837. | 3.2 | 277 |
| 295 | Cerebrospinal Fluid Catecholamine Levels as Predictors of Outcome in Subarachnoid Hemorrhage. Cerebrovascular Diseases, 2012, 33, 173-181. | 0.8 | 32 |
| 296 | Succinate Dehydrogenase (SDH) D Subunit (SDHD) Inactivation in a Growth-Hormone-Producing Pituitary Tumor: A New Association for SDH?. Journal of Clinical Endocrinology and Metabolism, 2012, 97, E357-E366. | 1.8 | 134 |
| 297 | Succinate Dehydrogenase Kidney Cancer: An Aggressive Example of the Warburg Effect in Cancer. Journal of Urology, 2012, 188, 2063-2071. | 0.2 | 211 |
| 298 | Usefulness of [18F]-DA and [18F]-DOPA for PET imaging in a mouse model of pheochromocytoma. Nuclear Medicine and Biology, 2012, 39, 215-226. | 0.3 | 13 |
| 299 | Subclinical phaeochromocytoma. Best Practice and Research in Clinical Endocrinology and Metabolism, 2012, 26, 507-515. | 2.2 | 76 |
| 300 | Characterization of two mouse models of metastatic pheochromocytoma using bioluminescence imaging. Cancer Letters, 2012, 316, 46-52. | 3.2 | 22 |
| 301 | Plasma methoxytyramine: A novel biomarker of metastatic pheochromocytoma and paraganglioma in relation to established risk factors of tumour size, location and SDHB mutation status. European Journal of Cancer, 2012, 48, 1739-1749. | 1.3 | 304 |
| 302 | NF- κ B inhibition significantly upregulates the norepinephrine transporter system, causes apoptosis in pheochromocytoma cell lines and prevents metastasis in an animal model. International Journal of Cancer, 2012, 131, 2445-2455. | 2.3 | 34 |
| 303 | Missense mutations in the human SDHB gene increase protein degradation without altering intrinsic enzymatic function. FASEB Journal, 2012, 26, 4506-4516. | 0.2 | 46 |
| 304 | New Roles of Carboxypeptidase E in Endocrine and Neural Function and Cancer. Endocrine Reviews, 2012, 33, 216-253. | 8.9 | 95 |
| 305 | EANM 2012 guidelines for radionuclide imaging of phaeochromocytoma and paraganglioma. European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39, 1977-1995. | 3.3 | 223 |
| 306 | Warburg Effect TM s Manifestation in Aggressive Pheochromocytomas and Paragangliomas: Insights from a Mouse Cell Model Applied to Human Tumor Tissue. PLoS ONE, 2012, 7, e40949. | 1.1 | 32 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 307 | Murine Models and Cell Lines for the Investigation of Pheochromocytoma: Applications for Future Therapies?. <i>Endocrine Pathology</i> , 2012, 23, 43-54. | 5.2 | 30 |
| 308 | Determinants of Central Sympathetic Activation in Spontaneous Primary Subarachnoid Hemorrhage. <i>Neurocritical Care</i> , 2012, 16, 381-388. | 1.2 | 26 |
| 309 | Measurements of Plasma Methoxytyramine, Normetanephrine, and Metanephrine as Discriminators of Different Hereditary Forms of Pheochromocytoma. <i>Clinical Chemistry</i> , 2011, 57, 411-420. | 1.5 | 282 |
| 310 | Hypertension in Pheochromocytoma: Characteristics and Treatment. <i>Endocrinology and Metabolism Clinics of North America</i> , 2011, 40, 295-311. | 1.2 | 153 |
| 311 | Current Role of Metaiodobenzylguanidine in the Diagnosis of Pheochromocytoma and Medullary Thyroid Cancer. <i>Seminars in Nuclear Medicine</i> , 2011, 41, 364-368. | 2.5 | 61 |
| 312 | When is a phaeo not a phaeo? Depression in an adolescent leading to a phaeochromocytoma-like biochemical profile. <i>Clinical Endocrinology</i> , 2011, 75, 567-568. | 1.2 | 1 |
| 313 | Metastatic pheochromocytoma: Does the size and age matter?. <i>European Journal of Clinical Investigation</i> , 2011, 41, 1121-1128. | 1.7 | 42 |
| 314 | Comparison of clinical and imaging features in succinate dehydrogenase-positive versus sporadic paragangliomas. <i>Surgery</i> , 2011, 150, 1186-1193. | 1.0 | 15 |
| 315 | CSF Catecholamine Profile in Subarachnoid Hemorrhage Patients with Neurogenic Cardiomyopathy. <i>Neurocritical Care</i> , 2011, 14, 401-406. | 1.2 | 11 |
| 316 | Functional Imaging of <i>SDHx</i> -Related Head and Neck Paragangliomas: Comparison of ¹⁸ F-Fluorodihydroxyphenylalanine, ¹⁸ F-Fluorodopamine, ¹⁸ F-Fluoro-2-Deoxy-D-Glucose PET, ¹²³ I-Metaiodobenzylguanidine Scintigraphy, and ¹¹¹ In-Pentetretotide Scintigraphy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, 2779-2785. | 1.8 | 129 |
| 317 | Age at Diagnosis of Pheochromocytoma Differs According to Catecholamine Phenotype and Tumor Location. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, 375-384. | 1.8 | 90 |
| 318 | Drugs and Pheochromocytoma – Don't Be Fooled by Every Elevated Metanephrine. <i>New England Journal of Medicine</i> , 2011, 364, 2268-2270. | 13.9 | 95 |
| 319 | Increased uptake of [123I]meta-iodobenzylguanidine, [18F]fluorodopamine, and [3H]norepinephrine in mouse pheochromocytoma cells and tumors after treatment with the histone deacetylase inhibitors. <i>Endocrine-Related Cancer</i> , 2011, 18, 143-157. | 1.6 | 37 |
| 320 | Metastatic Pheochromocytoma/Paraganglioma Related to Primary Tumor Development in Childhood or Adolescence: Significant Link to <i>SDHB</i> Mutations. <i>Journal of Clinical Oncology</i> , 2011, 29, 4137-4142. | 0.8 | 170 |
| 321 | Bilateral Adrenal Medullary Hyperplasia Associated With an <i>SDHB</i> Mutation. <i>Journal of Clinical Oncology</i> , 2011, 29, e200-e202. | 0.8 | 33 |
| 322 | Pheochromocytoma and Paraganglioma: Current Functional and Future Molecular Imaging. <i>Frontiers in Oncology</i> , 2011, 1, 58. | 1.3 | 33 |
| 323 | Drugs and pheochromocytoma–don't be fooled by every elevated metanephrine. <i>New England Journal of Medicine</i> , 2011, 364, 2268-70. | 13.9 | 21 |
| 324 | An N-terminal truncated carboxypeptidase E splice isoform induces tumor growth and is a biomarker for predicting future metastasis in human cancers. <i>Journal of Clinical Investigation</i> , 2011, 121, 880-892. | 3.9 | 61 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 325 | Pharmacologic Modulation of Serine/Threonine Phosphorylation Highly Sensitizes PHEO in a MPC Cell and Mouse Model to Conventional Chemotherapy. <i>PLoS ONE</i> , 2011, 6, e14678. | 1.1 | 32 |
| 326 | The North American Neuroendocrine Tumor Society Consensus Guideline for the Diagnosis and Management of Neuroendocrine Tumors. <i>Pancreas</i> , 2010, 39, 775-783. | 0.5 | 493 |
| 327 | Tyrosine hydroxylase, chromogranin A, and steroidogenic acute regulator as markers for successful separation of human adrenal medulla. <i>Cell and Tissue Research</i> , 2010, 340, 607-612. | 1.5 | 15 |
| 328 | Exercise-induced nausea and vomiting: another sign and symptom of pheochromocytoma and paraganglioma. <i>Endocrine</i> , 2010, 37, 403-407. | 1.1 | 19 |
| 329 | Genetic Testing for Pheochromocytoma. <i>Current Hypertension Reports</i> , 2010, 12, 456-464. | 1.5 | 56 |
| 330 | Metastatic Paraganglioma. <i>Seminars in Oncology</i> , 2010, 37, 627-637. | 0.8 | 91 |
| 331 | Development and validation of a comprehensive mutation and deletion detection assay for SDHB, SDHC, and SDHD. <i>Clinical Biochemistry</i> , 2010, 43, 700-704. | 0.8 | 5 |
| 332 | New imaging approaches to phaeochromocytomas and paragangliomas. <i>Clinical Endocrinology</i> , 2010, 72, 137-145. | 1.2 | 112 |
| 333 | Response to Letter to the Editor by Dullaart <i><i>etÂal.</i></i> . <i>Clinical Endocrinology</i> , 2010, 72, 569-570. | 1.2 | 0 |
| 334 | Catecholamine metabolomic and secretory phenotypes in phaeochromocytoma. <i>Endocrine-Related Cancer</i> , 2010, 18, 97-111. | 1.6 | 169 |
| 335 | Minimal changes in environmental temperature result in a significant increase in energy expenditure and changes in the hormonal homeostasis in healthy adults. <i>European Journal of Endocrinology</i> , 2010, 163, 863-872. | 1.9 | 80 |
| 336 | Succinate dehydrogenase gene mutations are strongly associated with paraganglioma of the organ of Zuckerkandl. <i>Endocrine-Related Cancer</i> , 2010, 17, 581-588. | 1.6 | 30 |
| 337 | Factors influencing arterial stiffness in pheochromocytoma and effect of adrenalectomy. <i>Hypertension Research</i> , 2010, 33, 454-459. | 1.5 | 34 |
| 338 | The Use of Functional Imaging in a Patient with Head and Neck Paragangliomas. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, 481-482. | 1.8 | 20 |
| 339 | Low Sensitivity of Glucagon Provocative Testing for Diagnosis of Pheochromocytoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, 238-245. | 1.8 | 27 |
| 340 | SDH-related pheochromocytoma and paraganglioma. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2010, 24, 415-424. | 2.2 | 78 |
| 341 | Gs1± Deficiency in Adipose Tissue Leads to a Lean Phenotype with Divergent Effects on Cold Tolerance and Diet-Induced Thermogenesis. <i>Cell Metabolism</i> , 2010, 11, 320-330. | 7.2 | 38 |
| 342 | In vivo micro-CT imaging of liver lesions in small animal models. <i>Methods</i> , 2010, 50, 20-25. | 1.9 | 38 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 343 | Functional and Oncologic Outcomes of Partial Adrenalectomy for Pheochromocytoma in Patients With von Hippel-Lindau Syndrome After at Least 5 Years of Followup. <i>Journal of Urology</i> , 2010, 184, 1855-1859. | 0.2 | 66 |
| 344 | Pheochromocytoma and Paraganglioma. <i>Progress in Brain Research</i> , 2010, 182, 343-373. | 0.9 | 58 |
| 345 | Partial Adrenalectomy: Underused First Line Therapy for Small Adrenal Tumors. <i>Journal of Urology</i> , 2010, 184, 18-25. | 0.2 | 85 |
| 346 | Monoamine Oxidase A-mediated Enhanced Catabolism of Norepinephrine Contributes to Adverse Remodeling and Pump Failure in Hearts With Pressure Overload. <i>Circulation Research</i> , 2010, 106, 193-202. | 2.0 | 187 |
| 347 | Diagnosis of pheochromocytoma with special emphasis on MEN2 syndrome. <i>Hormones</i> , 2009, 8, 111-116. | 0.9 | 36 |
| 348 | Overexpression of Interleukin-13 Receptor- $\alpha 2$ in Neuroendocrine Malignant Pheochromocytoma: A Novel Target for Receptor Directed Anti-Cancer Therapy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 2952-2957. | 1.8 | 25 |
| 349 | Comparison of ^{18}F -Fluoro-L-DOPA, ^{18}F -Fluoro-Deoxyglucose, and ^{18}F -Fluorodopamine PET and ^{123}I -MIBG Scintigraphy in the Localization of Pheochromocytoma and Paraganglioma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 4757-4767. | 1.8 | 361 |
| 350 | Mediastinal paragangliomas: association with mutations in the succinate dehydrogenase genes and aggressive behavior. <i>Endocrine-Related Cancer</i> , 2009, 16, 291-299. | 1.6 | 42 |
| 351 | Clinical aspects of SDHx-related pheochromocytoma and paraganglioma. <i>Endocrine-Related Cancer</i> , 2009, 16, 391-400. | 1.6 | 117 |
| 352 | Usefulness of ^{123}I -MIBG Scintigraphy in the Evaluation of Patients with Known or Suspected Primary or Metastatic Pheochromocytoma or Paraganglioma: Results from a Prospective Multicenter Trial. <i>Journal of Nuclear Medicine</i> , 2009, 50, 1448-1454. | 2.8 | 139 |
| 353 | Noninvasive monitoring of a murine model of metastatic pheochromocytoma: A comparison of contrast-enhanced microCT and nonenhanced MRI. <i>Journal of Magnetic Resonance Imaging</i> , 2009, 29, 685-691. | 1.9 | 34 |
| 354 | Update on pediatric pheochromocytoma. <i>Pediatric Nephrology</i> , 2009, 24, 943-950. | 0.9 | 102 |
| 355 | Malignant paraganglioma associated with succinate dehydrogenase subunit B in an 8-year-old child: the age of first screening?. <i>Pediatric Nephrology</i> , 2009, 24, 1239-1242. | 0.9 | 17 |
| 356 | Characterization of an animal model of aggressive metastatic pheochromocytoma linked to a specific gene signature. <i>Clinical and Experimental Metastasis</i> , 2009, 26, 239-250. | 1.7 | 62 |
| 357 | Use of ^{18}F -fluorodopamine positron emission tomography (PET) as first-line investigation for the diagnosis and localization of non-metastatic and metastatic pheochromocytoma (PHEO). <i>Clinical Endocrinology</i> , 2009, 71, 11-17. | 1.2 | 74 |
| 358 | Central Nervous System Imprinting of the G Protein Gs α and Its Role in Metabolic Regulation. <i>Cell Metabolism</i> , 2009, 9, 548-555. | 7.2 | 118 |
| 359 | A Reduction in Pten Tumor Suppressor Activity Promotes ErbB-2-Induced Mouse Prostate Adenocarcinoma Formation through the Activation of Signaling Cascades Downstream of PDK1. <i>American Journal of Pathology</i> , 2009, 174, 2051-2060. | 1.9 | 18 |
| 360 | An immunohistochemical procedure to detect patients with paraganglioma and pheochromocytoma with germline SDHB, SDHC, or SDHD gene mutations: a retrospective and prospective analysis. <i>Lancet Oncology</i> , 2009, 10, 764-771. | 5.1 | 477 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 361 | Radiofrequency Ablation of Metastatic Pheochromocytoma. <i>Journal of Vascular and Interventional Radiology</i> , 2009, 20, 1483-1490. | 0.2 | 51 |
| 362 | Candidate Genes Associated With Malignant Pheochromocytomas by Genome-Wide Expression Profiling. <i>Annals of Surgery</i> , 2009, 250, 983-990. | 2.1 | 23 |
| 363 | Brief Communication: Radiographic Contrast Infusion and Catecholamine Release in Patients With Pheochromocytoma. <i>Annals of Internal Medicine</i> , 2009, 150, 27. | 2.0 | 48 |
| 364 | Gender-related differences in the clinical presentation of malignant and benign pheochromocytoma. <i>Endocrine</i> , 2008, 34, 96-100. | 1.1 | 16 |
| 365 | Metastasis-associated gene expression profile of liver and subcutaneous lesions derived from mouse pheochromocytoma cells. <i>Molecular Carcinogenesis</i> , 2008, 47, 245-251. | 1.3 | 15 |
| 366 | Treatment of malignant pheochromocytoma/paraganglioma with cyclophosphamide, vincristine, and dacarbazine. <i>Cancer</i> , 2008, 113, 2020-2028. | 2.0 | 234 |
| 367 | Unexplained Symptomatic Paroxysmal Hypertension in Pseudopheochromocytoma. <i>Annals of the New York Academy of Sciences</i> , 2008, 1148, 469-478. | 1.8 | 15 |
| 368 | Pheochromocytoma. <i>Annals of the New York Academy of Sciences</i> , 2008, 1148, 462-468. | 1.8 | 22 |
| 369 | Clinical and molecular genetics of patients with the Carney-Stratakis syndrome and germline mutations of the genes coding for the succinate dehydrogenase subunits SDHB, SDHC, and SDHD. <i>European Journal of Human Genetics</i> , 2008, 16, 79-88. | 1.4 | 446 |
| 370 | Mutations associated with succinate dehydrogenase <scpd>-related malignant paragangliomas. <i>Clinical Endocrinology</i> , 2008, 68, 561-566. | 1.2 | 44 |
| 371 | A clinical overview of pheochromocytomas/paragangliomas and carcinoid tumors. <i>Nuclear Medicine and Biology</i> , 2008, 35, S27-S34. | 0.3 | 64 |
| 372 | Differential expression of the regulated catecholamine secretory pathway in different hereditary forms of pheochromocytoma. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2008, 295, E1223-E1233. | 1.8 | 66 |
| 373 | Role of positron emission tomography and bone scintigraphy in the evaluation of bone involvement in metastatic pheochromocytoma and paraganglioma: specific implications for succinate dehydrogenase enzyme subunit B gene mutations. <i>Endocrine-Related Cancer</i> , 2008, 15, 311-323. | 1.6 | 60 |
| 374 | Pheochromocytoma crisis induced by glucocorticoids: a report of four cases and review of the literature. <i>European Journal of Endocrinology</i> , 2008, 158, 423-429. | 1.9 | 86 |
| 375 | Comparison of ¹⁸ F-Fluorodopamine PET with ¹²³ I-Metaiodobenzylguanidine and ¹¹¹ In-Pentetreotide Scintigraphy in Localization of Nonmetastatic and Metastatic Pheochromocytoma. <i>Journal of Nuclear Medicine</i> , 2008, 49, 1613-1619. | 2.8 | 137 |
| 376 | Biochemically Silent Abdominal Paragangliomas in Patients with Mutations in the Succinate Dehydrogenase Subunit B Gene. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008, 93, 4826-4832. | 1.8 | 111 |
| 377 | Pheochromocytoma. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2008, 5, E1-E1. | 3.3 | 7 |
| 378 | Preoperative Management of the Pheochromocytoma Patient. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 4069-4079. | 1.8 | 497 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 379 | Adenoviral Gene Transfer in Bovine Adrenomedullary and Murine Pheochromocytoma Cells: Potential Clinical and Therapeutic Relevance. <i>Endocrinology</i> , 2007, 148, 3900-3907. | 1.4 | 5 |
| 380 | Elevated Inflammation Markers in Pheochromocytoma Compared to Other Forms of Hypertension. <i>NeuroImmunoModulation</i> , 2007, 14, 57-64. | 0.9 | 38 |
| 381 | Mitochondrial Localization of Human Recombinant Adenovirus: From Evolution to Gene Therapy. <i>NeuroImmunoModulation</i> , 2007, 14, 221-223. | 0.9 | 5 |
| 382 | The Incidentally Discovered Adrenal Mass. <i>New England Journal of Medicine</i> , 2007, 356, 2005-2006. | 13.9 | 20 |
| 383 | Clinical Presentations, Biochemical Phenotypes, and Genotype-Phenotype Correlations in Patients with Succinate Dehydrogenase Subunit B-Associated Pheochromocytomas and Paragangliomas. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 779-786. | 1.8 | 262 |
| 384 | Brown Fat Imaging with 18F-6-Fluorodopamine PET/CT, 18F-FDG PET/CT, and 123I-MIBG SPECT: A Study of Patients Being Evaluated for Pheochromocytoma. <i>Journal of Nuclear Medicine</i> , 2007, 48, 1077-1083. | 2.8 | 92 |
| 385 | The Effects of Carbidopa on Uptake of 6-18F-Fluoro-L-DOPA in PET of Pheochromocytoma and Extraadrenal Abdominal Paraganglioma. <i>Journal of Nuclear Medicine</i> , 2007, 48, 1599-1606. | 2.8 | 101 |
| 386 | Usefulness of Standardized Uptake Values for Distinguishing Adrenal Glands with Pheochromocytoma from Normal Adrenal Glands by Use of 6-18F-Fluorodopamine PET. <i>Journal of Nuclear Medicine</i> , 2007, 48, 1940-1944. | 2.8 | 23 |
| 387 | Is Supine Rest Necessary before Blood Sampling for Plasma Metanephrines?. <i>Clinical Chemistry</i> , 2007, 53, 352-354. | 1.5 | 110 |
| 388 | Superiority of Fluorodeoxyglucose Positron Emission Tomography to Other Functional Imaging Techniques in the Evaluation of Metastatic SDHB-Associated Pheochromocytoma and Paraganglioma. <i>Journal of Clinical Oncology</i> , 2007, 25, 2262-2269. | 0.8 | 316 |
| 389 | Proteomic profiling of von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2 pheochromocytomas reveals different expression of chromogranin B. <i>Endocrine-Related Cancer</i> , 2007, 14, 463-471. | 1.6 | 14 |
| 390 | The role of 6-[18F]fluorodopamine positron emission tomography in the localization of adrenal pheochromocytoma associated with von Hippel-Lindau syndrome. <i>European Journal of Endocrinology</i> , 2007, 156, 483-487. | 1.9 | 78 |
| 391 | Neuropeptide Y expression in pheochromocytomas: relative absence in tumours from patients with von Hippel-Lindau syndrome. <i>Journal of Endocrinology</i> , 2007, 193, 225-233. | 1.2 | 14 |
| 392 | Familial pheochromocytomas and paragangliomas associated with mutations of the succinate dehydrogenase genes. <i>Expert Review of Endocrinology and Metabolism</i> , 2007, 2, 399-406. | 1.2 | 2 |
| 393 | Sympathoadrenal function in patients with paroxysmal hypertension: pseudopheochromocytoma. <i>Journal of Hypertension</i> , 2007, 25, 2286-2295. | 0.3 | 42 |
| 394 | ErbB-2 Induces Bilateral Adrenal Pheochromocytoma Formation in Mice. <i>Cell Cycle</i> , 2007, 6, 1946-1950. | 1.3 | 17 |
| 395 | The optimal imaging of adrenal tumours: a comparison of different methods. <i>Endocrine-Related Cancer</i> , 2007, 14, 587-599. | 1.6 | 218 |
| 396 | Current Treatment of Malignant Pheochromocytoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 1217-1225. | 1.8 | 180 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 397 | Adverse Drug Reactions in Patients with Pheochromocytoma. <i>Drug Safety</i> , 2007, 30, 1031-1062. | 1.4 | 122 |
| 398 | Pheochromocytoma: recommendations for clinical practice from the First International Symposium. <i>Nature Clinical Practice Endocrinology and Metabolism</i> , 2007, 3, 92-102. | 2.9 | 581 |
| 399 | An assessment of biochemical tests for the diagnosis of pheochromocytoma. <i>Nature Clinical Practice Endocrinology and Metabolism</i> , 2007, 3, 744-745. | 2.9 | 19 |
| 400 | Cardiac sympathetic denervation preceding motor signs in Parkinson disease. <i>Clinical Autonomic Research</i> , 2007, 17, 118-121. | 1.4 | 88 |
| 401 | Emergencies Caused by Pheochromocytoma, Neuroblastoma, or Ganglioneuroma. <i>Endocrinology and Metabolism Clinics of North America</i> , 2006, 35, 699-724. | 1.2 | 65 |
| 402 | Utility of Plasma Free Metanephrines in Diagnosis of Factitious Pheochromocytoma. <i>Endocrine Practice</i> , 2006, 12, 568-571. | 1.1 | 9 |
| 403 | Uncommon Endocrine Tumors in Children and Adolescents. , 2006, , 775-797. | | 1 |
| 404 | Discordant localization of 2-[18F]-fluoro-2-deoxy-D-glucose in 6-[18F]-fluorodopamine- and [123I]-metaiodobenzylguanidine-negative metastatic pheochromocytoma sites. <i>Nuclear Medicine Communications</i> , 2006, 27, 31-36. | 0.5 | 85 |
| 405 | Characteristics of Blood Pressure in Pheochromocytoma. <i>Annals of the New York Academy of Sciences</i> , 2006, 1073, 86-93. | 1.8 | 14 |
| 406 | Transcriptional Regulation of Phenylethanolamine N-Methyltransferase in Pheochromocytomas from Patients with von Hippel-Lindau Syndrome and Multiple Endocrine Neoplasia Type 2. <i>Annals of the New York Academy of Sciences</i> , 2006, 1073, 241-252. | 1.8 | 24 |
| 407 | Animal Models of Pheochromocytoma Including NIH Initial Experience. <i>Annals of the New York Academy of Sciences</i> , 2006, 1073, 300-305. | 1.8 | 9 |
| 408 | Biochemical Diagnosis and Localization of Pheochromocytoma: Can We Reach a Consensus?. <i>Annals of the New York Academy of Sciences</i> , 2006, 1073, 332-347. | 1.8 | 115 |
| 409 | Current Trends in Functional Imaging of Pheochromocytomas and Paragangliomas. <i>Annals of the New York Academy of Sciences</i> , 2006, 1073, 374-382. | 1.8 | 50 |
| 410 | Anatomical and Functional Imaging of Tumors in Animal Models: Focus on Pheochromocytoma. <i>Annals of the New York Academy of Sciences</i> , 2006, 1073, 392-404. | 1.8 | 11 |
| 411 | Gene Expression Profiling of Benign and Malignant Pheochromocytoma. <i>Annals of the New York Academy of Sciences</i> , 2006, 1073, 541-556. | 1.8 | 59 |
| 412 | Somatic VHLgene alterations in MEN2-associated medullary thyroid carcinoma. <i>BMC Cancer</i> , 2006, 6, 131. | 1.1 | 29 |
| 413 | MicroCT for high-resolution imaging of ectopic pheochromocytoma tumors in the liver of nude mice. <i>International Journal of Cancer</i> , 2006, 119, 2236-2241. | 2.3 | 30 |
| 414 | High Frequency ofSDHBGermline Mutations in Patients with Malignant Catecholamine-Producing Paragangliomas: Implications for Genetic Testing. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006, 91, 4505-4509. | 1.8 | 299 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 415 | Increased blood pressure variability in pheochromocytoma compared to essential hypertension patients. <i>Journal of Hypertension</i> , 2005, 23, 2033-2039. | 0.3 | 45 |
| 416 | Plasma metanephrines in renal failure. <i>Kidney International</i> , 2005, 67, 668-677. | 2.6 | 73 |
| 417 | Downregulation of metastasis suppressor genes in malignant pheochromocytoma. <i>International Journal of Cancer</i> , 2005, 114, 139-143. | 2.3 | 92 |
| 418 | Expression of the noradrenaline transporter and phenylethanolamine N-methyltransferase in normal human adrenal gland and pheochromocytoma. <i>Cell and Tissue Research</i> , 2005, 322, 443-453. | 1.5 | 22 |
| 419 | Pheochromocytoma Catecholamine Phenotypes and Prediction of Tumor Size and Location by Use of Plasma Free Metanephrines. <i>Clinical Chemistry</i> , 2005, 51, 735-744. | 1.5 | 177 |
| 420 | Differential Expression of Erythropoietin and Its Receptor in von Hippel-Lindau-Associated and Multiple Endocrine Neoplasia Type 2-Associated Pheochromocytomas. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 3747-3751. | 1.8 | 26 |
| 421 | Cushing's Syndrome Due to Ectopic Corticotropin Secretion: Twenty Years' Experience at the National Institutes of Health. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 4955-4962. | 1.8 | 588 |
| 422 | Biochemical and Clinical Manifestations of Dopamine-Producing Paragangliomas: Utility of Plasma Methoxytyramine. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 2068-2075. | 1.8 | 213 |
| 423 | Different expression of catecholamine transporters in pheochromocytomas from patients with von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2. <i>European Journal of Endocrinology</i> , 2005, 153, 551-563. | 1.9 | 57 |
| 424 | Pheochromocytoma. <i>Lancet</i> , The, 2005, 366, 665-675. | 6.3 | 1,462 |
| 425 | Combined corticotropin-releasing hormone and glucocorticoid deficiency does not enhance counterregulatory responses after recurrent hypoglycemia in mice. <i>Metabolism: Clinical and Experimental</i> , 2005, 54, 1259-1265. | 1.5 | 7 |
| 426 | New functional imaging modalities for chromaffin tumors, neuroblastomas and ganglioneuromas. <i>Trends in Endocrinology and Metabolism</i> , 2005, 16, 66-72. | 3.1 | 65 |
| 427 | Leptin concentrations in the abdominal subcutaneous adipose tissue of patients with anorexia nervosa assessed by in vivo microdialysis. <i>Regulatory Peptides</i> , 2005, 128, 63-68. | 1.9 | 26 |
| 428 | A New Concept of Unopposed β_2 -Adrenergic Overstimulation in a Patient with Pheochromocytoma. <i>Annals of Internal Medicine</i> , 2005, 142, 1026. | 2.0 | 11 |
| 429 | Current Approaches and Recommended Algorithm for the Diagnostic Localization of Pheochromocytoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004, 89, 479-491. | 1.8 | 296 |
| 430 | The Role of [18F]Fluorodeoxyglucose Positron Emission Tomography and [111In]-Diethylenetriaminepentaacetate-d-Phe-Pentetreotide Scintigraphy in the Localization of Ectopic Adrenocorticotropin-Secreting Tumors Causing Cushing's Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004, 89, 2214-2221. | 1.8 | 133 |
| 431 | Malignant pheochromocytoma: current status and initiatives for future progress. <i>Endocrine-Related Cancer</i> , 2004, 11, 423-436. | 1.6 | 299 |
| 432 | Cardiac Uptake-1 Inhibition by High Circulating Norepinephrine Levels in Patients with Pheochromocytoma. <i>Hypertension</i> , 2004, 43, 1227-1232. | 1.3 | 15 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 433 | Diagnosis and Localization of Pheochromocytoma. <i>Hypertension</i> , 2004, 43, 907-910. | 1.3 | 40 |
| 434 | Functional Imaging of Endocrine Tumors: Role of Positron Emission Tomography. <i>Endocrine Reviews</i> , 2004, 25, 568-580. | 8.9 | 145 |
| 435 | Anatomical and Functional Imaging of Metastatic Pheochromocytoma. <i>Annals of the New York Academy of Sciences</i> , 2004, 1018, 495-504. | 1.8 | 40 |
| 436 | Laparoscopic Management of Extra-Adrenal Pheochromocytoma. <i>Journal of Urology</i> , 2004, 171, 72-76. | 0.2 | 50 |
| 437 | Pheochromocytoma as an endocrine emergency. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2003, 4, 121-128. | 2.6 | 87 |
| 438 | Diagnostic Localization of Malignant Bladder Pheochromocytoma Using 6-[¹⁸ F]Fluorodopamine Positron Emission Tomography. <i>Journal of Urology</i> , 2003, 169, 274-275. | 0.2 | 24 |
| 439 | Endocrine Withdrawal Syndromes. <i>Endocrine Reviews</i> , 2003, 24, 523-538. | 8.9 | 144 |
| 440 | Biochemical Diagnosis of Pheochromocytoma: How to Distinguish True- from False-Positive Test Results. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003, 88, 2656-2666. | 1.8 | 447 |
| 441 | Superiority of 6-[¹⁸ F]-Fluorodopamine Positron Emission Tomography Versus [¹³¹ I]-Metaiodobenzylguanidine Scintigraphy in the Localization of Metastatic Pheochromocytoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003, 88, 4083-4087. | 1.8 | 237 |
| 442 | Localization of Medullary Thyroid Carcinoma Metastasis in a Multiple Endocrine Neoplasia Type 2A Patient by 6-[¹⁸ F]-Fluorodopamine Positron Emission Tomography. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003, 88, 637-641. | 1.8 | 64 |
| 443 | Loss of Meal-Induced Decrease in Plasma Ghrelin Levels in Patients with Anorexia Nervosa. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003, 88, 1678-1682. | 1.8 | 142 |
| 444 | Effects of Hypo- and Hyperthyroidism on Noradrenergic Activity and Glycerol Concentrations in Human Subcutaneous Abdominal Adipose Tissue Assessed with Microdialysis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003, 88, 5605-5608. | 1.8 | 48 |
| 445 | Diagnostic Imaging of Pheochromocytoma. , 2003, 31, 107-120. | | 12 |
| 446 | Biochemical Diagnosis of Pheochromocytoma. , 2003, 31, 76-106. | | 54 |
| 447 | Hypotension in a Woman with a Metastatic Dopamine-Secreting Carotid Body Tumor. <i>Endocrine Practice</i> , 2003, 9, 310-314. | 1.1 | 25 |
| 448 | Survivin: a novel neuroendocrine marker for pheochromocytoma. <i>European Journal of Endocrinology</i> , 2002, 146, 381-388. | 1.9 | 31 |
| 449 | Utility of Plasma Free Metanephrines for Detecting Childhood Pheochromocytoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002, 87, 1955-1960. | 1.8 | 104 |
| 450 | The Molecular Pathogenesis of Hereditary and Sporadic Adrenocortical and Adrenomedullary Tumors. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002, 87, 5367-5384. | 1.8 | 174 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 451 | Biochemical Diagnosis of Pheochromocytoma. JAMA - Journal of the American Medical Association, 2002, 287, 1427-34. | 3.8 | 994 |
| 452 | Management of Malignant Pheochromocytoma. , 2002, 12, 291-299. | | 11 |
| 453 | Chronic Hypercortisolemia Inhibits Dopamine Synthesis and Turnover in the Nucleus accumbens: An in vivo Microdialysis Study. Neuroendocrinology, 2002, 76, 148-157. | 1.2 | 41 |
| 454 | Diagnostic Localization of Pheochromocytoma. Annals of the New York Academy of Sciences, 2002, 970, 170-176. | 1.8 | 60 |
| 455 | Choice of biochemical test for diagnosis of pheochromocytoma: Validation of plasma metanephrines. Current Hypertension Reports, 2002, 4, 250-255. | 1.5 | 25 |
| 456 | Local sympathetic function in human skeletal muscle and adipose tissue assessed by microdialysis. Clinical Autonomic Research, 2002, 12, 13-19. | 1.4 | 10 |
| 457 | Somatic VHL gene deletion and point mutation in MENâ€™2A-associated pheochromocytoma. Oncogene, 2002, 21, 479-482. | 2.6 | 33 |
| 458 | New Insights into the Genetics of Familial Chromaffin Cell Tumors. Annals of the New York Academy of Sciences, 2002, 970, 11-28. | 1.8 | 54 |
| 459 | New Advances in the Biochemical Diagnosis of Pheochromocytoma. Annals of the New York Academy of Sciences, 2002, 970, 29-40. | 1.8 | 68 |
| 460 | Genomic Medicine. Annals of the New York Academy of Sciences, 2002, 970, 177-192. | 1.8 | 3 |
| 461 | Pheochromocytoma in von Hippel-Lindau Disease: Distinct Histopathologic Phenotype Compared to Pheochromocytoma in Multiple Endocrine Neoplasia Type 2. Endocrine Pathology, 2002, 13, 17-28. | 5.2 | 74 |
| 462 | The role of dopamine in methylene blue-mediated inhibition of estradiol benzoate-induced anterior pituitary hyperplasia in rats. Neuroscience Letters, 2001, 304, 194-198. | 1.0 | 4 |
| 463 | INCREASED PLASMA NOREPINEPHRINE CONCENTRATION IN CATS WITH INTERSTITIAL CYSTITIS. Journal of Urology, 2001, 165, 2051-2054. | 0.2 | 64 |
| 464 | Recent Advances in Genetics, Diagnosis, Localization, and Treatment of Pheochromocytoma. Annals of Internal Medicine, 2001, 134, 315. | 2.0 | 512 |
| 465 | Understanding catecholamine metabolism as a guide to the biochemical diagnosis of pheochromocytoma. Reviews in Endocrine and Metabolic Disorders, 2001, 2, 297-311. | 2.6 | 156 |
| 466 | Allelic imbalance of the mutant and wild-type RET allele in MEN 2A-associated medullary thyroid carcinoma. Oncogene, 2001, 20, 7809-7811. | 2.6 | 46 |
| 467 | Pheochromocytomas in von Hippel-Lindau Syndrome and Multiple Endocrine Neoplasia Type 2 Display Distinct Biochemical and Clinical Phenotypes. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 1999-2008. | 1.8 | 262 |
| 468 | 6- [¹⁸ F]Fluorodopamine Positron Emission Tomographic (PET) Scanning for Diagnostic Localization of Pheochromocytoma. Hypertension, 2001, 38, 6-8. | 1.3 | 215 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 469 | Radiofrequency Ablation: a Novel Approach for Treatment of Metastatic Pheochromocytoma. Journal of the National Cancer Institute, 2001, 93, 648-649. | 3.0 | 83 |
| 470 | A "Pheo" Lurks: Novel Approaches for Locating Occult Pheochromocytoma. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 3641-3646. | 1.8 | 51 |
| 471 | INCREASED PLASMA NOREPINEPHRINE CONCENTRATION IN CATS WITH INTERSTITIAL CYSTITIS. Journal of Urology, 2001, 165, 2051-2054. | 0.2 | 25 |
| 472 | CRH Deficiency Impairs but Does Not Block Pituitary-Adrenal Responses to Diverse Stressors. Neuroendocrinology, 2000, 71, 79-87. | 1.2 | 68 |
| 473 | Impaired Basal and Restraint-Induced Epinephrine Secretion in Corticotropin-Releasing Hormone-Deficient Mice. Endocrinology, 2000, 141, 1142-1150. | 1.4 | 78 |
| 474 | Paternal versus maternal transmission of a stimulatory G-protein β subunit knockout produces opposite effects on energy metabolism. Journal of Clinical Investigation, 2000, 105, 615-623. | 3.9 | 151 |
| 475 | How do levels of (endogenous) glucocorticoids, interleukin-10 and interleukin-12 relate to multiple sclerosis relapse before, during and after pregnancy?. Clinical Endocrinology, 1999, 50, 818-819. | 1.2 | 7 |
| 476 | Heterogeneous neurochemical responses to different stressors: a test of Selye's doctrine of nonspecificity. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 1998, 275, R1247-R1255. | 0.9 | 119 |
| 477 | Regulation of Peripheral Catecholamine Responses to Acute Stress in Young Adult and Aged F-344 Rats. Stress, 1997, 2, 113-122. | 0.8 | 15 |
| 478 | Stressor-Specific Activation of Catecholaminergic Systems: Implications for Stress-Related Hypothalamic-Pituitary-Adrenocortical Responses. Advances in Pharmacology, 1997, 42, 561-564. | 1.2 | 27 |
| 479 | Hyperinsulinemia and Sympathoadrenal System Activity in the Rat. Annals of the New York Academy of Sciences, 1997, 827, 118-134. | 1.8 | 11 |
| 480 | Chronic blockade of nitric oxide synthesis elevates plasma levels of catecholamines and their metabolites at rest and during stress in rats. Neurochemical Research, 1997, 22, 995-1001. | 1.6 | 23 |
| 481 | Triiodothyronine attenuates estradiol-induced increases in dopamine D-2 receptor number in rat anterior pituitary. Brain Research, 1996, 712, 148-152. | 1.1 | 11 |
| 482 | Interrelations between Sympathoadrenal System and Hypothalamo-Pituitary-Adrenocortical/Thyroid Systems in Rats Exposed to Cold Stress. Journal of Neuroendocrinology, 1996, 8, 533-541. | 1.2 | 64 |
| 483 | Brainstem Hemisection Decreases Corticotropin-Releasing Hormone mRNA in the Paraventricular Nucleus but not in the Central Amygdaloid Nucleus. Journal of Neuroendocrinology, 1996, 8, 543-551. | 1.2 | 31 |
| 484 | Disprocynium24, a novel inhibitor of the extraneuronal monoamine transporter, has potent effects on the inactivation of circulating noradrenaline and adrenaline in conscious rat. Naunyn-Schmiedeberg's Archives of Pharmacology, 1996, 354, 287-94. | 1.4 | 34 |
| 485 | Plasma Metadrenalines: Do they Provide Useful Information about Sympatho-Adrenal Function and Catecholamine Metabolism?. Clinical Science, 1995, 88, 533-542. | 1.8 | 105 |
| 486 | Stress-Induced Norepinephrine Release in the Hypothalamic Paraventricular Nucleus and Pituitary-Adrenocortical and Sympathoadrenal Activity: In Vivo Microdialysis Studies. Frontiers in Neuroendocrinology, 1995, 16, 89-150. | 2.5 | 348 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 487 | Effects of immobilization on in vivo release of norepinephrine in the bed nucleus of the stria terminalis in conscious rats. <i>Brain Research</i> , 1995, 688, 242-246. | 1.1 | 92 |
| 488 | Effects of hypercortisolemia or hyperinsulinemia on neurochemical indices of catecholamine release and synthesis in conscious rats. <i>Journal of the Autonomic Nervous System</i> , 1995, 54, 104-112. | 1.9 | 2 |
| 489 | Effects of Various Stressors on In Vivo Norepinephrine Release in the Hypothalamic Paraventricular Nucleus and on the Pituitary-Adrenocortical Axis. <i>Annals of the New York Academy of Sciences</i> , 1995, 771, 115-130. | 1.8 | 141 |
| 490 | The neuronal and extraneuronal origins of plasma 3-methoxy-4-hydroxyphenylglycol in rats. <i>Journal of the Autonomic Nervous System</i> , 1994, 50, 93-107. | 1.9 | 39 |
| 491 | Role of CRH in Glucopenia-Induced Adrenomedullary Activation in Rats. <i>Journal of Neuroendocrinology</i> , 1993, 5, 475-486. | 1.2 | 30 |
| 492 | Glycine stimulates striatal dopamine release in conscious rats. <i>British Journal of Pharmacology</i> , 1993, 110, 50-53. | 2.7 | 37 |
| 493 | Effects of Single or Repeated Immobilization on Release of Norepinephrine and Its Metabolites in the Central Nucleus of the Amygdala in Conscious Rats. <i>Neuroendocrinology</i> , 1993, 57, 626-633. | 1.2 | 64 |
| 494 | Stress-Induced Norepinephrine Release in the Paraventricular Nucleus of Rats with Brainstem Hemisections: A Microdialysis Study. <i>Neuroendocrinology</i> , 1993, 58, 196-201. | 1.2 | 62 |
| 495 | Noradrenergic activation in the paraventricular nucleus during acute and chronic immobilization stress in rats: an in vivo microdialysis study. <i>Brain Research</i> , 1992, 589, 91-96. | 1.1 | 110 |
| 496 | Sympathoneural and skeletal muscle contributions to plasma DOPA responses in pithed rats. <i>Journal of the Autonomic Nervous System</i> , 1991, 35, 169-174. | 1.9 | 3 |
| 497 | Pediatric Metastatic Pheochromocytoma and Paraganglioma: Clinical Presentation and Diagnosis, Genetics, and Therapeutic Approaches. <i>Frontiers in Endocrinology</i> , 0, 13, . | 1.5 | 6 |